Pharmaceutical composition comprising GPC3 / TRGV9 binding protein and use thereof

By adding buffers and surfactants to the GPC3/TRGV9 binding protein and adjusting the pH and concentration, the problem of poor stability of the GPC3/TRGV9 binding protein was solved, resulting in better therapeutic effects.

WO2026237974A1PCT designated stage Publication Date: 2026-11-19JIANGSU HENGRUI MEDICINE CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/096556
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-13
Filing Date
2026-05-13
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

The GPC3/TRGV9 binding protein has a large molecular weight and complex structure, making it prone to degradation and resulting in poor stability, which affects the therapeutic effect.

Method used

Develop pharmaceutical compositions containing GPC3/TRGV9 binding proteins, using buffers such as acetate, citrate, succinate, histidine, phosphate, etc., combined with surfactants such as poloxamer, polysorbate, sugars such as sucrose and disodium edetate, and adjusting pH and concentration to improve stability.

Benefits of technology

It improves the stability and therapeutic efficacy of GPC3/TRGV9 binding proteins, making them suitable for drug delivery and maintaining activity during storage and use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2026096556-FTAPPB-I100001
    Figure PCTCN2026096556-FTAPPB-I100001
  • Figure PCTCN2026096556-FTAPPB-I100002
    Figure PCTCN2026096556-FTAPPB-I100002
  • Figure PCTCN2026096556-FTAPPB-I100003
    Figure PCTCN2026096556-FTAPPB-I100003
Patent Text Reader

Abstract

A pharmaceutical composition comprising a GPC3 / TRGV9 binding protein and a use thereof. Provided is a pharmaceutical composition, comprising a GPC3 / TRGV9 binding protein and a buffer.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical compositions containing GPC3 / TRGV9 binding protein and their uses

[0001] This disclosure claims priority to Chinese patent application 202510610715.7 and incorporates the text of the aforementioned patent application in its entirety. Technical Field

[0002] This disclosure pertains to the field of pharmaceutical formulations, and specifically relates to a pharmaceutical composition comprising a GPC3 / TRGV9 binding protein, its use therein, and its use as a medicine. Background Technology

[0003] γδT cells are a group of naturally occurring T cells capable of recognizing and killing tumor cells. They possess both antigen-presenting and cytotoxic functions, bridging innate and adaptive immunity. Unlike αβTCRs, the two chains that make up the γδT cell TCR are the γ chain and the δ chain, and their antigen recognition is not restricted by MHC (Exp Mol Med. 2021 Mar; 53(3):318-327). γδT cells are relatively few in number, accounting for approximately 1%-5% of PBMCs. Based on the different δ chains, they can be divided into four categories: δ1, δ2, δ3, and δ5 (Front Immunol. 2022 Jun 16; 13:915837), with δ1 and δ2 being the most numerous. δ1 can pair with different γ chains to form different TCRs, and is mainly distributed in tissues such as skin and mucous membranes; δ2 mainly pairs with γ9 to form the γ9δ2 subtype, which is mainly distributed in peripheral blood, accounting for up to 95% of the total number of peripheral blood γδ T cells (Front Immunol. 2022 Jun 16; 13:915837).

[0004] γδT cells play a crucial role in anti-tumor activity, employing various mechanisms to kill tumor cells. These include recognizing the phosphorylated BTN2A / BTN3A complex activated by the TCR on target cells, initiating a killing signal, and exerting their killing function. Additionally, they exhibit a killing pathway similar to NK cells, expressing receptors such as NKG2D on their cell surface, which bind to corresponding ligands on tumor cells to exert tumor-killing effects. γδT cells infiltrate to varying degrees in various tumors. A large-scale analysis of 5782 tumors across 25 tumor types revealed that γδT cell infiltration predicts a good prognosis and represents the most favorable cell population among all immune cells. Analysis of 3238 samples from 14 non-brain cancer solid tumors also indicated that γδT cell infiltration is an indicator of good prognosis (Oncoimmunology. 2017 Feb 6; 6(3):e1284723). Early clinical studies of γδT cells mainly focused on two approaches: in vivo activation and in vitro expansion followed by reinfusion. Although the anti-tumor effects shown by different studies were relatively limited, no serious side effects were reported, suggesting that γδT cells have good safety.

[0005] Glypican-3 (GPC3) is a potential target for liver cancer treatment. In 2020, there were 900,000 new cases of liver cancer and 830,000 deaths worldwide; in China, there were 410,000 new cases and 390,000 deaths in 2020; about half of the world's liver cancer cases occurred in China. In recent years, significant progress has been made in first-line or second-line treatment of advanced liver cancer, but effective treatments for later-line treatments are still lacking. GPC3 is a heparan sulfate proteoglycan composed of 580 amino acids, which is anchored to the cell membrane via glycosylphosphatidylinositol. GPC3 is highly expressed in various tumor tissues; for example, the positive rate of GPC3 in hepatocellular carcinoma is as high as 90%. In normal tissues, GPC3 expression is very limited, only expressed in the placenta and endometrium; and the expression level in the endometrium is much lower than that in tumor tissue, making it an ideal anti-tumor target (Sci Transl Med. 2017 Oct 4; 9(410):eaal4291).

[0006] This disclosure provides a novel sequence structure for an antibody targeting γδTCR, and constructs a bispecific antibody by combining it with a tumor-associated antigen (e.g., GPC3) binding domain (e.g., antibody). The bispecific antibody binds to a TAA (e.g., GPC3) at one end and to γδTCR at the other end, and can recruit and activate γδT cells to specifically kill TAA (e.g., GPC3) positive tumor cells, which significantly improves the efficacy of γδT cell therapy.

[0007] However, due to the large molecular weight and complex structure of GPC3 / TRGV9 binding proteins, they are prone to degradation and polymerization, becoming unstable and leading to reduced activity or even inactivation. Therefore, developing stable formulations of drugs is crucial to ensure that these binding proteins are suitable for drug delivery and maintain stability during storage and subsequent use, thereby achieving better efficacy. Summary of the Invention

[0008] This disclosure provides a pharmaceutical composition comprising a GPC3 / TRGV9 binding protein. It also provides a method for preparing the pharmaceutical composition, and methods for treating or preventing diseases, or related pharmaceutical uses.

[0009] This disclosure provides a pharmaceutical composition comprising a GPC3 / TRGV9 binding protein and a buffer.

[0010] In some embodiments, the buffer is selected from one or more of acetate buffers, citrate buffers, succinate buffers, histidine buffers, and phosphate buffers. In some specific embodiments, the buffer is selected from one or more of acetate-sodium acetate, citrate-sodium citrate, succinate-sodium succinate, histidine-histidine hydrochloride, and disodium hydrogen phosphate-sodium dihydrogen phosphate. "One or more" in this disclosure includes one, two, or more.

[0011] In some embodiments, the concentration of the buffer is from 1 mM to 100 mM, for example, 1 mM to 50 mM, 1 mM to 55 mM, 1 mM to 60 mM, 1 mM to 70 mM, 1 mM to 80 mM, 5 mM to 100 mM, 5 mM to 80 mM, 5 mM to 70 mM, 5 mM to 50 mM, 5 mM to 45 mM, 5 mM to 40 mM, 5 mM to 35 mM, 5 mM to 30 mM, 5 mM to 2... 5 mM, 5 mM to 20 mM, 5 mM to 10 mM, 10 mM to 20 mM, 10 mM to 30 mM, 10 mM to 35 mM, 10 mM to 40 mM, 10 mM to 50 mM, 15 mM to 20 mM, 15 mM to 25 mM, 15 mM to 35 mM, 15 mM to 50 mM, 20 mM to 35 mM, 1 mM to 10 mM, 1 mM to 20 mM, or any range between these values. In some embodiments, the concentration of the buffer is from 2 mM to 80 mM. In some embodiments, the concentration of the buffer is from 5 mM to 60 mM.

[0012] In some embodiments, the concentration of the buffer is about 1 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 22 mM, about 25 mM, about 26 mM, about 28 mM, about 30 mM, about 35 mM. mM, approximately 40mM, approximately 43mM, approximately 45mM, approximately 48mM, approximately 50mM, approximately 55mM, approximately 57mM, approximately 58mM, approximately 60mM, approximately 62mM, approximately 65mM, approximately 68mM, approximately 70mM, approximately 72mM, approximately 75mM, approximately 78mM, approximately 80mM, approximately 82mM, approximately 85mM, approximately 88mM, approximately 90mM, approximately 92mM, approximately 95mM, approximately 100mM. Or any range between any of the aforementioned point values.

[0013] In some embodiments, the buffer or the pharmaceutical composition has a pH value of 3.0 to 7.0, for example, 3.5 to 7.0, 4.0 to 7.0, 4.0 to 6.5, 4.0 to 6.0, 4.0 to 5.5, 4.0 to 5.0, 4.0 to 4.8, 4.0 to 4.5, 4.8 to 5.0, 5.0 to 5.5, 5.5 to 6.0, 5.0 to 6.0, 4.5 to 4.8, or any range between these values. In some embodiments, the buffer or the pharmaceutical composition has a pH value of 4.0 to 7.0. In some embodiments, the buffer or the pharmaceutical composition has a pH value of 4.0 to 6.5.

[0014] In some embodiments, the pH value of the buffer or the pharmaceutical composition is about 3.0, about 3.1, about 3.2, about 3.3, about 3.4, about 3.5, about 3.6, about 3.7, about 3.8, about 3.9, about 4.0, about 4.1, about 4.2, about 4.3, about 4.4, about 4.5, about 4.6, about 4.7, about 4.8, about 4.9, about 5.0, about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 6.7, about 6.8, about 6.9, or about 7.0, or any range between any of the aforementioned values.

[0015] Typically, the pH of a pharmaceutical composition obtained by replacing a buffer is almost identical to the pH of the buffer. However, it is known to those skilled in the art that pH drift may sometimes occur during pharmaceutical formulation, but the pH drift of the pharmaceutical formulation is generally small (e.g., within ±0.8). In some embodiments, the pH drift of the pharmaceutical formulation is within ±0.5.

[0016] In some embodiments, the concentration of the GPC3 / TRGV9 binding protein is from 0.01 mg / mL to 200 mg / mL, for example, 0.1 mg / mL to 200 mg / mL, 0.5 mg / mL to 200 mg / mL, 0.5 mg / mL to 100 mg / mL, 0.5 mg / mL to 80 mg / mL, 0.5 mg / mL to 50 mg / mL, 1 mg / mL to 200 mg / mL, 1 mg / mL to 100 mg / mL, 1 mg / mL Up to 80 mg / mL, 1 mg / mL to 50 mg / mL, 50 mg / mL to 100 mg / mL, 5 mg / mL to 200 mg / mL, 10 mg / mL to 200 mg / mL, 10 mg / mL to 180 mg / mL, 10 mg / mL to 160 mg / mL, 10 mg / mL to 150 mg / mL, 10 mg / mL to 120 mg / mL, 10 mg / mL to 110 mg / mL, 10 mg / mL to 100 mg / mL, 10 mg / mL to 80mg / mL, 10mg / mL to 60mg / mL, 10mg / mL to 40mg / mL, 20mg / mL to 200mg / mL, 20mg / mL to 180mg / mL, 20mg / mL to 150mg / mL, 20mg / mL to 120mg / mL, 20mg / mL to 110mg / mL, 20mg / mL to 100mg / mL, 20mg / mL to 80mg / mL, 20mg / mL to 60mg / mL, 2 0 mg / mL to 40 mg / mL, 40 mg / mL to 120 mg / mL, 40 mg / mL to 110 mg / mL, 40 mg / mL to 100 mg / mL, 40 mg / mL to 80 mg / mL, 40 mg / mL to 60 mg / mL, 60 mg / mL to 80 mg / mL, 60 mg / mL to 120 mg / mL, 60 mg / mL to 150 mg / mL, 80 mg / mL to 120 mg / mL, or any range between these values.

[0017] In some embodiments, the concentration of the GPC3 / TRGV9 binding protein is about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, or about 0.5 mg / mL (approx. 1 mg / mL), approximately 5 mg / mL, approximately 10 mg / mL, approximately 15 mg / mL, approximately 20 mg / mL, approximately 25 mg / mL, approximately 30 mg / mL, approximately 35 mg / mL, approximately 40 mg / mL, approximately 45 mg / mL, approximately 50 mg / mL, approximately 55 mg / mL, approximately 60 mg / mL, approximately 61 mg / mL, approximately 62 mg / mL, approximately 63 mg / mL, approximately 64 mg / mL, approximately 65 mg / mL, approximately 66 mg / mL, approximately 67 mg / mL, approximately 68 mg / mL, approximately 69 mg / mL, approximately 70 mg / mL, approximately 71 mg / mL, approximately 72 mg / mL, approximately 73 mg / mL, approximately 7 4 mg / mL, approximately 75 mg / mL, approximately 76 mg / mL, approximately 77 mg / mL, approximately 78 mg / mL, approximately 79 mg / mL, approximately 80 mg / mL, approximately 81 mg / mL, approximately 82 mg / mL, approximately 83 mg / mL, approximately 84 mg / mL, approximately 85 mg / mL, approximately 86 mg / mL, approximately 87 mg / mL, approximately 88 mg / mL, approximately 89 mg / mL, approximately 90 mg / mL, approximately 91 mg / mL, approximately 92 mg / mL, approximately 93 mg / mL, approximately 94 mg / mL, approximately 95 mg / mL, approximately 96 mg / mL, approximately 97 mg / mL, approximately 98 mg / mL, approximately 99 mg / mL, approximately 100 mg / mL Approximately 101 mg / mL, approximately 102 mg / mL, approximately 103 mg / mL, approximately 104 mg / mL, approximately 105 mg / mL, approximately 106 mg / mL, approximately 107 mg / mL, approximately 108 mg / mL, approximately 109 mg / mL, approximately 110 mg / mL, approximately 111 mg / mL, approximately 112 mg / mL, approximately 113 mg / mL, approximately 114 mg / mL, approximately 115 mg / mL, approximately 116 mg / mL, approximately 117 mg / mL, approximately 118 mg / mL, approximately 119 mg / mL, approximately 120 mg / mL, approximately 121 mg / mL, approximately 122 mg / mL, approximately 123 mg / mL, approximately 124 mg / mL Approximately 125 mg / mL, approximately 126 mg / mL, approximately 127 mg / mL, approximately 128 mg / mL, approximately 129 mg / mL, approximately 130 mg / mL, approximately 131 mg / mL, approximately 132 mg / mL, approximately 133 mg / mL, approximately 134 mg / mL, approximately 135 mg / mL, approximately 140 mg / mL, approximately 145 mg / mL, approximately 150 mg / mL, approximately 155 mg / mL, approximately 160 mg / mL, approximately 165 mg / mL, approximately 170 mg / mL, approximately 175 mg / mL, approximately 180 mg / mL, approximately 185 mg / mL, approximately 190 mg / mL, approximately 195 mg / mL, approximately 200 mg / mL. Or any range between any of the aforementioned values.

[0018] In some embodiments, the pharmaceutical composition as described in any of the preceding embodiments comprises a surfactant. In some embodiments, the surfactant is a nonionic surfactant. In some embodiments, the surfactant is selected from poloxamer (e.g., poloxamer 188), polysorbates (e.g., polysorbate 20 (i.e., PS20), polysorbate 80 (i.e., PS80)), polyhydroxyalkanoates, Triton, sodium lauryl sulfonate, sodium lauryl sulfonate, sodium octyl glycoside, lauryl-sulfobetaine, myristyl-sulfobetaine, linoleyl-sulfobetaine, stearyl-sulfobetaine, lauryl-sarcosine, myristyl-sarcosine, linoleyl-sarcosine, stearyl-sarcosine, linoleyl-saccharide, linoleyl-saccharide, succinate ... Betaine, myristyl-betaine, cetyl-betaine, lauramidopropyl-betaine, cocarbamate-propyl-betaine, linoleamide-propyl-betaine, myristamidopropyl-betaine, palmitoamide-propyl-betaine, isostearamidopropyl-betaine, myristamidopropyl-dimethylamine, palmitoamide-propyl-dimethylamine, isostearamidopropyl-dimethylamine, sodium methyl cocoyl, sodium methyl oleate, polyethylene glycol, polypropylene glycol, copolymers of ethylene and propylene glycol, etc., or any combination thereof. In some embodiments, the surfactant is sodium dodecyl sulfate (SDS) or polysorbate. In some embodiments, the surfactant is polysorbate 80.

[0019] In some embodiments, the concentration of the surfactant is from 0.01 to 10.0 mg / mL, for example, 0.01 to 9.0 mg / mL, 0.01 to 8.0 mg / mL, 0.01 to 7.0 mg / mL, 0.01 to 6.0 mg / mL, 0.01 to 5.0 mg / mL, 0.01 to 4.0 mg / mL, 0.01 to 3.0 mg / mL, 0.01 to 2.0 mg / mL, 0.01 to 1.9 mg / mL, 0.01 to 1.8 mg / mL, 0.1-2 mg / mL, 0.1-4 mg / mL, 0.1-5 mg / mL, and any range between these values.

[0020] In some embodiments, the concentration of the surfactant is about 0.01 mg / mL, about 0.02 mg / mL, about 0.03 mg / mL, about 0.04 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.2 mg / mL, about 0.3 mg / mL, about 0.4 mg / mL, about 0.5 mg / mL, about 0.6 mg / mL, about 0.7 mg / mL, about 0.8 mg / mL, about 0.9 mg / mL, about 1.0 mg / mL, about 1.1 mg / mL, about 1.2 mg / mL, about 1.3 mg / mL, about 1.4 mg / mL, about 1.5 mg / mL, about 1.8 mg / mL, or about 2 mg / mL.

[0021] In some embodiments, the pharmaceutical composition comprises sugars.

[0022] In some embodiments, the sugar is selected from glucose, sucrose, trehalose, lactose, fructose, and maltose. In some embodiments, the sugar is sucrose or trehalose; in some specific embodiments, the sugar is sucrose.

[0023] In some embodiments, the concentration of the sugar is 1-200 mg / mL, for example 1-190 mg / mL, 1-180 mg / mL, 1-160 mg / mL, 1-150 mg / mL, 1-100 mg / mL, 10-100 mg / mL, 20-100 mg / mL, 30-100 mg / mL, 20-150 mg / mL, 30-180 mg / mL, 10-180 mg / mL, 30-150 mg / mL, and any range between these values.

[0024] In some embodiments, the concentration of the sugar is about 10 mg / mL, about 20 mg / mL, about 30 mg / mL, about 40 mg / mL, about 50 mg / mL, about 60 mg / mL, about 70 mg / mL, about 80 mg / mL, about 90 mg / mL, about 100 mg / mL, about 110 mg / mL, about 120 mg / mL, or about 1250 mg / mL, or any range between these values.

[0025] In some embodiments, the pharmaceutical composition further comprises disodium edetate.

[0026] In some embodiments, the concentration of the disodium edetate is 0.01-10 mg / mL, for example 0.01-9 mg / mL, 0.01-8 mg / mL, 0.01-6 mg / mL, 0.01-4 mg / mL, 0.01-2 mg / mL, 0.01-1 mg / mL, and any range between these values. In some embodiments, the concentration of the disodium edetate is about 0.01 mg / mL, about 0.02 mg / mL, about 0.03 mg / mL, about 0.04 mg / mL, about 0.05 mg / mL, about 0.06 mg / mL, about 0.07 mg / mL, about 0.08 mg / mL, about 0.09 mg / mL, about 0.1 mg / mL, about 0.2 mg / mL, about 0.3 mg / mL, about 0.4 mg / mL, about 0.5 mg / mL, about 0.6 mg / mL, about 0.7 mg / mL, about 0.8 mg / mL, and about... 0.9 mg / mL, approximately 1.0 mg / mL, approximately 1.1 mg / mL, approximately 1.2 mg / mL, approximately 1.3 mg / mL, approximately 1.4 mg / mL, approximately 1.5 mg / mL, approximately 1.6 mg / mL, approximately 1.7 mg / mL, approximately 1.8 mg / mL, approximately 1.9 mg / mL, approximately 2.0 mg / mL, approximately 3.0 mg / mL, approximately 4.0 mg / mL, approximately 5.0 mg / mL, approximately 6.0 mg / mL, approximately 7.0 mg / mL, approximately 8.0 mg / mL, approximately 9.0 mg / mL, approximately 10.0 mg / mL. Or any range between these values.

[0027] In some embodiments, the pharmaceutical composition comprises:

[0028] (1) GPC3 / TRGV9 binding protein at concentrations ranging from 0.01 mg / mL to 200 mg / mL,

[0029] 1mM to 100mM histidine-histidine hydrochloride

[0030] 1 mg / mL to 200 mg / mL sucrose,

[0031] 0.01 mg / mL to 5.00 mg / mL polysorbate 80, and

[0032] 0.01 mg / mL to 10 mg / mL disodium edetate,

[0033] The pH of the pharmaceutical composition is from 3.0 to 7.0;

[0034] or

[0035] (1-1) GPC3 / TRGV9 binding protein at concentrations ranging from 0.5 mg / mL to 100 mg / mL.

[0036] 10mM to 50mM histidine-histidine hydrochloride

[0037] 30 mg / mL to 100 mg / mL sucrose,

[0038] 0.1 mg / mL to 2.00 mg / mL polysorbate 80, and

[0039] 0.01 mg / mL to 1 mg / mL disodium edetate,

[0040] The pH of the pharmaceutical composition is 5.0 to 6.0;

[0041] or

[0042] (1-2) GPC3 / TRGV9 binding protein at concentrations ranging from 0.5 mg / mL to 100 mg / mL.

[0043] 10mM to 50mM histidine-histidine hydrochloride

[0044] 30 mg / mL to 100 mg / mL sucrose,

[0045] 0.1 mg / mL to 2.00 mg / mL poloxamer 188, and

[0046] 0.01 mg / mL to 1 mg / mL disodium edetate,

[0047] The pH of the pharmaceutical composition is 5.0 to 6.0;

[0048] or

[0049] (1-3) 50 mg / mL to 100 mg / mL of GPC3 / TRGV9 binding protein,

[0050] Approximately 20 mM histidine-histidine hydrochloride,

[0051] Approximately 75 mg / mL of sucrose.

[0052] Approximately 0.4 mg / mL of polysorbate 80, and

[0053] Approximately 0.02 mg / mL of disodium edetate.

[0054] The pH of the pharmaceutical composition is 5.0 to 6.0;

[0055] or

[0056] (1-4) GPC3 / TRGV9 binding protein at concentrations ranging from 0.5 mg / mL to 50 mg / mL.

[0057] Approximately 20 mM histidine-histidine hydrochloride,

[0058] Approximately 80 mg / mL of sucrose,

[0059] Approximately 0.2 mg / mL of polysorbate 80, and

[0060] Approximately 0.02 mg / mL of disodium edetate.

[0061] The pH of the pharmaceutical composition is 5.0 to 6.0;

[0062] (2) GPC3 / TRGV9 binding protein at concentrations ranging from 0.01 mg / mL to 200 mg / mL,

[0063] 1mM to 100mM acetate-sodium acetate,

[0064] 1-200 mg / mL sucrose,

[0065] 0.01 mg / mL to 5.00 mg / mL polysorbate 80, and

[0066] 0.01 mg / mL to 10 mg / mL disodium edetate,

[0067] The pH of the pharmaceutical composition is 3 to 7;

[0068] or

[0069] (3) GPC3 / TRGV9 binding protein at concentrations ranging from 0.01 mg / mL to 200 mg / mL,

[0070] 1mM to 100mM citric acid-sodium citrate,

[0071] 1-200 mg / mL sucrose,

[0072] 0.01 mg / mL to 5.00 mg / mL polysorbate 80, and

[0073] 0.01 mg / mL to 10 mg / mL disodium edetate,

[0074] The pH of the pharmaceutical composition is 3 to 7;

[0075] or

[0076] (4) GPC3 / TRGV9 binding protein at concentrations ranging from 0.01 mg / mL to 200 mg / mL,

[0077] 1mM to 100mM succinic acid-sodium succinate

[0078] 1-200 mg / mL sucrose,

[0079] 0.01 mg / mL to 5.00 mg / mL polysorbate 80, and

[0080] 0.01 mg / mL to 10 mg / mL disodium edetate,

[0081] The pH of the pharmaceutical composition is 3 to 7;

[0082] or

[0083] (5) GPC3 / TRGV9 binding protein at concentrations ranging from 0.01 mg / mL to 200 mg / mL,

[0084] 1mM to 100mM disodium hydrogen phosphate-sodium dihydrogen phosphate salt,

[0085] 1 mg / mL to 200 mg / mL sucrose,

[0086] 0.01 mg / mL to 5.00 mg / mL polysorbate 80, and

[0087] 0.01 mg / mL to 10 mg / mL disodium edetate,

[0088] The pH of the pharmaceutical composition is 3 to 7.

[0089] T cell receptor γ variable region 9 (TRGV9) binding protein

[0090] This disclosure provides a TRGV9 binding protein. In some embodiments, it is capable of binding the TCR. In some embodiments, it is capable of binding the γδTCR. In some embodiments, it is capable of binding the γ9 chain of the TCR. In some embodiments, it is capable of binding the γ9δ2TCR. In other embodiments, it is capable of binding the γ9δ1TCR.

[0091] Some implementations provide a TRGV9 binding protein comprising:

[0092] 1) An immunoglobulin single variable domain, wherein the immunoglobulin single variable domain comprises CDR1, CDR2 and / or CDR3 in the amino acid sequence shown in SEQ ID NO: 5 or 26, for example, the immunoglobulin single variable domain comprises CDR3 in any of the amino acid sequences shown in SEQ ID NO: 5 or 26; or,

[0093] 2) Heavy chain variable region (VH1) and / or light chain variable region (VL1), wherein VH1 comprises HCDR1, HCDR2, and HCDR3 of the amino acid sequence shown in SEQ ID NO: 9 or 27, and VL1 comprises LCDR1, LCDR2, and LCDR3 of any of the amino acid sequences shown in SEQ ID NO: 10 or 28.

[0094] The CDR is defined according to the Kabat, IMGT, Chothia, AbM, or Contact numbering system, for example, it is defined according to the Kabat numbering system.

[0095] Some implementations provide a TRGV9 binding protein comprising:

[0096] 1) An immunoglobulin single variable domain, wherein the immunoglobulin single variable domain comprises CDR1, CDR2 and / or CDR3, wherein CDR1 comprises the amino acid sequence shown in SEQ ID NO: 6, CDR2 comprises the amino acid sequence shown in SEQ ID NO: 7, and CDR3 comprises the amino acid sequence shown in SEQ ID NO: 8; or,

[0097] 2) VH1 and / or VL1, wherein VH1 comprises HCDR1, HCDR2 and / or HCDR3, wherein HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 11, HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 12, and HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 13; and VL1 comprises LCDR1, LCDR2 and / or LCDR3, wherein LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 14, LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 15, and LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 16.

[0098] Some implementations provide a TRGV9 binding protein comprising:

[0099] 1) An immunoglobulin single variable domain, wherein the immunoglobulin single variable domain comprises CDR1, CDR2, and CDR3, respectively, as shown in SEQ ID NO: 6-8; or,

[0100] 2) VH1 and VL1, wherein VH1 comprises HCDR1, HCDR2 and HCDR3 with amino acid sequences as shown in SEQ ID NO: 11-13, and VL1 comprises LCDR1, LCDR2 and LCDR3 with amino acid sequences as shown in SEQ ID NO: 14-16, respectively.

[0101] In some implementations, the immunoglobulin single variable domain or VH1 or VL1 in the aforementioned protein are each independently humanized, reverse-mutated, affinity-matured, T-cell epitope removed / reduced, antibody deamidated, and / or antibody isomerized.

[0102] In some implementations, the heavy chain framework region of the human lineage template used for humanizing the immunoglobulin single variable domain in the aforementioned proteins is derived from IGHV3-64; the heavy chain framework region of the human lineage template used in the humanization process of VH1 is derived from IGHV3-21; and the light chain framework region of the human lineage template used in the humanization process of VL1 is derived from IGKV1-12.

[0103] Some implementations provide a TRGV9 binding protein comprising:

[0104] 1) An immunoglobulin single variable domain, wherein the immunoglobulin single variable domain comprises an amino acid sequence as shown in or having at least 80% or at least 90% identity with any of SEQ ID NO: 5 or 26; or,

[0105] 2) VH1 and VL1, wherein VH1 contains an amino acid sequence as shown in or having at least 80% or at least 90% identity with any of SEQ ID NO: 9 or 27, and VL1 contains an amino acid sequence as shown in or having at least 80% or at least 90% identity with any of SEQ ID NO: 10 or 28.

[0106] In some specific implementations, the TRGV9 binding protein comprises the following VH and VL:

[0107] 2-1) VH1 contains an amino acid sequence as shown in SEQ ID NO: 9 or having at least 80% or 90% identity with it, and VL1 contains an amino acid sequence as shown in SEQ ID NO: 10 or having at least 80% or 90% identity with it.

[0108] 2-2) VH1 contains an amino acid sequence as shown in SEQ ID NO: 27 or having at least 80% or at least 90% identity with it, and VL1 contains an amino acid sequence as shown in SEQ ID NO: 28 or having at least 80% or at least 90% identity with it.

[0109] In this disclosure, "at least 80% (sequence) identity" encompasses at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% (sequence) identity; "at least 90% (sequence) identity" encompasses at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% (sequence) identity.

[0110] In some embodiments, the aforementioned TRGV9 binding protein comprises or is an anti-TRGV9 antibody or its antigen-binding fragment. In some embodiments, the anti-TRGV9 antibody or its antigen-binding fragment is a recombinant antibody or a fragment thereof. In some embodiments, the anti-TRGV9 antibody is a monospecific antibody, a bispecific antibody, or a multispecific antibody (e.g., a trispecific antibody).

[0111] Wherein, when the aforementioned TRGV9 binding protein contains a single variable immunoglobulin domain, it can be a camel antibody, chimeric antibody, humanized antibody, fully human antibody, or its antigen-binding fragment. For example, the single variable immunoglobulin domain is a single-domain antibody or VHH. As an example, the aforementioned TRGV9 binding protein itself is a single-domain antibody or VHH. In some specific embodiments, the antibody or its antigen-binding fragment is a linear antibody, single-chain antibody, nanobody, peptide antibody, domain antibody and diabody, triabody and tetrabody, tandem di-scFv, or tandem tri-scFv.

[0112] Where the aforementioned TRGV9 binding protein contains VH and VL, it can be a murine antibody, chimeric antibody, humanized antibody, fully human antibody, or its antigen-binding fragment. In some specific embodiments, the antigen-binding fragment includes, but is not limited to: Fab, Fv, sFv, Fab', F(ab')2, linear antibody, single-chain antibody, scFv, sdAb, sdFv, nanobody, peptide antibody, domain antibody, diabody, triabody, and tetrabody, tandem di-scFv, and tandem tri-scFv. In some specific embodiments, the antigen-binding fragment includes Fab, Fv, sFv, Fab', and F(ab')2.

[0113] In some embodiments, the aforementioned TRGV9 binding protein may contain one or more (e.g., 2, 3, 4, 5, 6, 7, or 8) of the aforementioned immunoglobulin single variable domains. These immunoglobulin single variable domains may form dimer or multimer molecules. The immunoglobulin single variable domains may be homodimers or heterodimers.

[0114] In some implementations, the aforementioned TRGV9 binding protein may contain one or more (e.g., 2, 3, 4, 5, 6, 7, 8) of the aforementioned VH, VL, or combinations thereof.

[0115] In some embodiments, the aforementioned TRGV9 binding protein further includes a human immunoglobulin Fc region; for example, the Fc region is the Fc region of human IgG1, IgG2, IgG3, or IgG4. In some embodiments, the Fc region is the Fc region of human IgG1. In some specific embodiments, the Fc region may be an Fc region with reduced effector function; for example, the Fc region may have mutations. Exemplary IgG Fc regions with reduced effector function include those with the following substitutions: N297A or N297Q (IgG1); L234A / L235A (IgG1); V234A / G237A (IgG2); L235A / G237A / E318A (IgG4); H268Q / V309L / A330S / A331S (IgG2); C220S / C226S / C229S / P2 38S (IgG1); C226S / C229S / E233P / L234V / L235A (IgG1); L234F / L235E / P331S (IgG1); L234F / L235E (IgG1); L234F or L235E (IgG1); L234A or L235A (IgG1) or S267E / L328F (IgG1). For example, L234A / L235A indicates a sequence containing both L234A and L235A.

[0116] In some implementations, the aforementioned TRGV9 binding protein contains a single variable immunoglobulin domain or VH, VL, and Fc regions that are directly or indirectly linked by a linker. The linker may be a non-functional amino acid sequence of 1-20 or more amino acids without secondary structure or higher.

[0117] In some embodiments, the aforementioned TRGV9 binding protein is: a protein that specifically binds to γδTCR, or an anti-γδTCR antibody or its antigen-binding fragment; a protein that specifically binds to the γ9 chain of TCR, or an anti-TCR γ9 chain antibody or its antigen-binding fragment; a protein that specifically binds to the variable region (Vγ9) of the γ9 chain of TCR, or an anti-Vγ9TCR antibody or its antigen-binding fragment; a protein that specifically binds to γ9δ2TCR, or an anti-γ9δ2TCR antibody or its antigen-binding fragment; a protein that specifically binds to γ9δ1TCR, or an anti-γ9δ1TCR antibody or its antigen-binding fragment; or a protein that specifically binds to TRGV9, or an anti-TRGV9 antibody or its antigen-binding fragment.

[0118] In some implementations, the aforementioned TRGV9 binding protein has a function or property selected from at least one of the following:

[0119] (a) EC with ≤10 nM 50 The EC binds to γ9δ2T cells. 50For example, ≤5nM, ≤4nM, ≤3nM, ≤2nM, ≤1nM, ≤0.5nM, ≤0.2nM, ≤0.1nM. The EC 50 It is obtained through FACS detection, which is a commonly used affinity detection method in the field, such as that described in Embodiment 5 of this disclosure.

[0120] (b) Specifically binds to the γ9 chain of TCR, for example, specifically binds to γ9δ1TCR and γ9δ2TCR;

[0121] (c) γ8 chains that do not bind to TCR (cannot be detected by testing methods), for example, those that do not bind to γ8δ2TCR;

[0122] (d) The variable region (TRGV9) of the γ9 chain that specifically binds to TCR;

[0123] (e) Specifically binds to VγδCαβ chimeric TCRs, but does not bind to VαβCγδ chimeric TCRs;

[0124] (f) Binding to cynomolgus monkey γ9δ2TCR;

[0125] Wherein, (b)-(e) can be obtained by conventional detection methods in the art, such as those described in Embodiment 4 of this disclosure.

[0126] In some implementations, the aforementioned protein binds to the K of TRGV9. D The value can be ≤1×10 -7 M, for example, ≤1×10 - 8 M, or ≤1×10 -9 M, or ≤1×10 -10 M.

[0127] In some embodiments, a protein is provided that binds to or competitively binds to the same antigenic epitope in the aforementioned TRGV9 binding protein of this disclosure, which is an immunoglobulin single variable domain.

[0128] In some embodiments, a protein is provided that binds to or competitively binds to the same antigenic epitopes as VH and VL in the aforementioned TRGV9 binding protein of this disclosure.

[0129] In some embodiments, a protein is provided whose binding to TRGV9 is blocked by a single immunoglobulin variable domain or VH and VL in the aforementioned TRGV9 binding protein of this disclosure.

[0130] GPC3 / TRGV9 binding protein

[0131] This disclosure provides a protein that binds GPC3 and TCR. In some embodiments, a protein is provided that binds GPC3 and γδTCR. In some embodiments, a protein is provided that binds the γ9 chain of GPC3 and TCR. In some embodiments, a protein is provided that binds the variable region (Vγ9) of the γ9 chain of GPC3 and TCR. In some embodiments, a protein is provided that binds GPC3 and γ9δ2TCR. In some embodiments, a protein is provided that binds GPC3 and γ9δ1TCR. In some embodiments, a protein is provided that binds GPC3 and TRGV9. In some embodiments, the "binding" is simultaneous or sequential binding.

[0132] This disclosure provides a binding protein that binds to tumor-associated antigens (TAAs), tumor-specific antigens, and TRGV9, comprising a binding domain for binding to a TAA (or tumor-specific antigen) and a binding domain for binding to TRGV9. In some embodiments, it comprises a first antigen-binding domain that specifically binds to a TAA (or tumor-specific antigen) and a second antigen-binding domain that specifically binds to TRGV9. In some embodiments, the second antigen-binding domain that specifically binds to TRGV9 is the aforementioned TRGV9 binding protein of this disclosure. In some embodiments, the second antigen-binding domain that specifically binds to TRGV9 is an immunoglobulin single variable domain in the aforementioned TRGV9 binding protein of this disclosure, and / or a combination of VH and VL.

[0133] In some implementations, a GPC3 / TRGV9 binding protein is provided, which includes a first antigen-binding domain that specifically binds to GPC3 and a second antigen-binding domain that specifically binds to TRGV9.

[0134] In some specific embodiments, the first antigen-binding domain comprises a heavy chain variable region (VH2) and / or a light chain variable region (VL2), wherein the VH2 comprises HCDR1, HCDR2, and HCDR3 of the amino acid sequence shown in SEQ ID NO: 33, and the VL2 comprises LCDR1, LCDR2, and LCDR3 of the amino acid sequence shown in SEQ ID NO: 34. In some specific embodiments, the first antigen-binding domain comprises a heavy chain variable region (VH2) and a light chain variable region (VL2), wherein the VH2 comprises HCDR1, HCDR2, and HCDR3 of the amino acid sequence shown in SEQ ID NO: 33, and the VL2 comprises LCDR1, LCDR2, and LCDR3 of the amino acid sequence shown in SEQ ID NO: 34, and the CDR is defined according to the Kabat, IMGT, Chothia, AbM, or Contact numbering system, for example, according to the Kabat numbering system.

[0135] In some specific embodiments, the first antigen-binding domain comprises a heavy chain variable region (VH2) and a light chain variable region (VL2), wherein the VH2 comprises HCDR1, HCDR2, and HCDR3, and the HCDR1, HCDR2, and HCDR3 each comprise the amino acid sequences shown in SEQ ID NO: 35-37; and the VL2 comprises LCDR1, LCDR2, and LCDR3, and the LCDR1, LCDR2, and LCDR3 each comprise the amino acid sequences shown in SEQ ID NO: 38-40.

[0136] In some specific implementations, the VH2 and / or VL2 are humanized, reverse-mutated, affinity-matured, T-cell epitope-removed / reduced, antibody deamidation-reduced, and / or antibody isomerization-reduced.

[0137] In some specific embodiments, VH2 comprises an amino acid sequence as shown in SEQ ID NO: 33 or having at least 80% or at least 90% sequence identity with it, and / or VL2 comprises an amino acid sequence as shown in SEQ ID NO: 34 or having at least 80% or at least 90% sequence identity with it.

[0138] In some implementations, a GPC3 / TRGV9 binding protein is provided, comprising either of the aforementioned first antigen-binding domains that specifically bind to GPC3 and a second antigen-binding domain that specifically binds to TRGV9.

[0139] In some embodiments, the aforementioned GPC3 / TRGV9 binding protein comprises or is an anti-GPC3 / TRGV9 antibody or its antigen-binding fragment. In some embodiments, the anti-GPC3 / TRGV9 antibody or its antigen-binding fragment is a recombinant antibody or a fragment thereof. In some embodiments, the anti-GPC3 / TRGV9 antibody is a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody). In some embodiments, the immunoglobulin single variable domain in the anti-GPC3 / TRGV9 antibody or its antigen-binding fragment is a single-domain antibody or VHH. In some specific embodiments, the antigen-binding fragment includes, but is not limited to: Fab, Fv, sFv, Fab', F(ab')2, linear antibodies, single-chain antibodies, scFv, sdAb, sdFv, nanobodies, peptide antibodies, domain antibodies, diabody, triabody and tetrabody, tandem di-scFv, and tandem tri-scFv.

[0140] In some embodiments, the aforementioned GPC3 / TRGV9 binding protein includes one or more (e.g., 2, 3, 4, 5, 6, 7, 8) of the aforementioned immunoglobulin single variable domains. In some embodiments, the aforementioned GPC3 / TRGV9 binding protein includes one or more (e.g., 2, 3, 4, 5, 6, 7, 8) of the aforementioned VH1 and VL1 combinations. In some embodiments, the aforementioned GPC3 / TRGV9 binding protein includes one or more (e.g., 2, 3, 4, 5, 6, 7, 8) of the aforementioned VH2 and VL2 combinations.

[0141] In some implementations, the aforementioned GPC3 / TRGV9 binding protein also includes the Fc region of human immunoglobulins; for example, the Fc region of human IgG1, IgG2, IgG3, or IgG4.

[0142] In some embodiments, the aforementioned GPC3 / TRGV9 binding protein further includes a human immunoglobulin Fc region; for example, the Fc region is the Fc region of human IgG1, IgG2, IgG3, or IgG4. In some embodiments, the Fc region is the Fc region of human IgG1. In some specific embodiments, the Fc region may be an Fc region with reduced effector function; for example, the Fc region may have mutations. Exemplary IgG Fc regions with reduced effector function include those with the following substitutions: N297A or N297Q (IgG1); L234A / L235A (IgG1); V234A / G237A (IgG2); L235A / G237A / E318A (IgG4); H268Q / V309L / A330S / A331S (IgG2); C220S / C226S / C229S / P2 38S (IgG1); C226S / C229S / E233P / L234V / L235A (IgG1); L234F / L235E / P331S (IgG1); L234F / L235E (IgG1); L234F or L235E (IgG1); L234A or L235A (IgG1) or S267E / L328F (IgG1).

[0143] In some specific embodiments, the Fc region comprises a first subunit (Fc1) and a second subunit (Fc2). In some specific embodiments, mutations are introduced that cause the two subunits (Fc1, Fc2) of the Fc region to pair and form a dimer, or mutations that reduce homodimerization. In some specific embodiments, the first and second subunits contain knock-in-hole mutations. For example, within the CH3 / CH3 interface, one, two, or more amino acid residues in the CH3 domain of Fc1 are mutated to one or more amino acid residues with a larger side chain volume, thereby creating a protrusion (or pestle, knob) on the surface of the CH3 domain of Fc1. Correspondingly, one, two, or more amino acid residues in the CH3 domain of Fc2 that interact with the CH3 domain of Fc1 are mutated to amino acid residues with a smaller side chain volume, thereby creating a depression (or hopper, hole) on the surface of the CH3 domain of Fc2. The first subunit (Fc1) and the second subunit (Fc2) are interchangeable only to distinguish the two different subunits.

[0144] In some specific embodiments, Fc1 contains one or more amino acid substitutions selected from positions 354, 356, 358, and 366, and Fc2 contains one or more amino acid substitutions selected from positions 349, 356, 358, 366, 368, and 407. In some specific embodiments, Fc1 contains a mutation at position 366, and Fc2 contains mutations selected from positions 366, 368, and 407, or any combination thereof. In some specific embodiments, Fc1 contains a mutation at position 354 or 356, and Fc2 contains a mutation at position 349. In some specific embodiments, Fc1 contains a mutation at position 354 or 356, and Fc2 contains mutations at positions 349, 366, 368, and 407.

[0145] In some specific embodiments, Fc1 contains one or more amino acid substitutions selected from 354C, 356E, 358M, and 366W, and Fc2 contains one or more amino acid substitutions selected from 349C, 356E, 358M, 366S, 368A, and 407V. In some specific embodiments, Fc1 contains a 366W mutation, and Fc2 contains a mutation selected from 366S, 368A, and 407V, or any combination thereof. In some specific embodiments, Fc1 contains a 354C or 356C mutation, and Fc2 contains a 349C mutation. Or in some specific embodiments, Fc1 contains a 354C / 366W mutation, and Fc2 contains a 349C / 366S / 368A / 407V mutation.

[0146] In some specific embodiments, Fc1 contains the T366W mutation, and Fc2 contains a mutation selected from T366S, L368A, and Y407V, or any combination thereof; Fc1 contains the S354C or E356C mutation, and Fc2 contains the Y349C mutation; or Fc1 contains the S354C / T366W mutation, and Fc2 contains the Y349C / T366S / L368A / Y407V mutation. In some specific embodiments, the amino acid sequence of Fc1 is as shown in SEQ ID NO: 52, and the amino acid sequence of Fc2 is as shown in SEQ ID NO: 53.

[0147] In some implementations, the aforementioned GPC3 / TRGV9 binding protein comprises reducing mismatches between the heavy and light chains by mutating the amino acid size and charge at the heavy chain CH1 and light chain CL interface. For example, Roche swapped the CH1 and CL domains and created the CrossMab platform (Schaefer et al., Proceedings of the National Academy of Sciences of the United States of America, 108(27), pp.11187–11192(2011)), MedImmune mutated the heavy chain F126C and light chain S121C to introduce disulfide bonds (Mazor et al., mAbs, 7(2), pp.377–389(2015)), Amgen further modified the CH1-CL region with electrostatic interactions (Liu et al., Journal of Biological Chemistry, 290(12), pp.7535–7562(2015)), and Lilly (Lewis et al., Nature... Biotechnology, 32(2), pp.191–198 (2014) and Genentech (Dillon et al., mAbs, 9(2), pp.213–230 (2017)) introduced mutations in both the variable and constant domains. WuXi AppTec replaced the constant region of the antibody with the constant region of the TCR, as described in CN109535257A (cited and incorporated in full).

[0148] In some implementations, the aforementioned GPC3 / TRGV9 binding protein includes a linker.

[0149] In some implementations, the immunoglobulin single variable domain or VH, VL and Fc regions in the aforementioned GPC3 / TRGV9 binding protein are directly or indirectly linked by a linker. The linker can be a non-functional amino acid sequence of 1-20 or more amino acids without secondary or higher structures. For example, the linker is such as (G... m Sn ) h or (G) m Q n ) h Or (GGNGT) h Or (YGNGT) h Or (EPKSS) h or (A) m S n ) h As shown, m and n are each independently selected from integers 1-8, and h is independently selected from integers 1-20. For example, the connectors are selected from G4S, GS, GAP, (G4S)2, (G4S)3, (G4S)4, (G4S)5, ASGS, A3S, etc.

[0150] In some embodiments, the GPC3 / TRGV9 binding protein comprises a combination selected from:

[0151] 1) The first heavy chain, the second heavy chain, and the light chain, among which,

[0152] The first chain, from N-terminus to C-terminus, consists of: [immunoglobulin single variable domain] - [linker 1] - [Fc1].

[0153] The second chain, from the N end to the C end, is as follows: [VH1]-[connector 2]-[CH1]-[connector 3]-[Fc2].

[0154] The light chain, from the N end to the C end, is as follows: [VL1]-[connector 4]-[CL];

[0155] or

[0156] The first chain, from N-terminus to C-terminus, consists of: [immunoglobulin single variable domain] - [linker 1] - [Fc2].

[0157] The second chain, from the N end to the C end, is as follows: [VH1]-[connector 2]-[CH1]-[connector 3]-[Fc1].

[0158] The light chain, from the N end to the C end, is as follows: [VL1]-[connector 4]-[CL];

[0159] Wherein, - represents a peptide bond, and the linker 1, linker 2, linker 3 and linker 4 may be the same or different, may exist independently or not, and may be independently selected from the linkers disclosed above;

[0160] In some specific implementations, connector 1 is AAAAS, while connectors 2, 3, and 4 are not present.

[0161] 2) First heavy chain, first light chain, second heavy chain, and second light chain, wherein,

[0162] The first chain, from N to C, is as follows: [VH2]-[connector 1]-[Obscurin-O chain]-[connector 2]-[Fc1].

[0163] The first light chain, from the N end to the C end, is as follows: [VL2] - [connector 3] - [Titin-T chain].

[0164] The second chain, from the N end to the C end, is as follows: [VH1]-[connector 4]-[CH1]-[connector 5]-[Fc2].

[0165] The second light chain, from the N end to the C end, is as follows: [VL1]-[connector 6]-[CL];

[0166] or,

[0167] The first chain, from N to C, is as follows: [VH1] - [connector 1] - [Obscurin-O chain] - [connector 2] - [Fc1].

[0168] The first light chain, from the N end to the C end, is as follows: [VL1] - [connector 3] - [Titin-T chain].

[0169] The second chain, from the N end to the C end, is as follows: [VH2]-[connector 4]-[CH1]-[connector 5]-[Fc2].

[0170] The second light chain, from the N end to the C end, is as follows: [VL2] - [connector 6] - [CL]

[0171] Wherein, - represents a peptide bond, and the linker 1, linker 2, linker 3, linker 4, linker 5 and linker 6 may be the same or different, may exist independently or not exist independently, and may be independently selected from the linkers disclosed above.

[0172] In some specific implementations, connectors 1 and 3 are GGGGS, while connectors 2, 4, 5, and 6 are not present.

[0173] 3) First heavy chain, first light chain, second heavy chain, and second light chain, wherein,

[0174] The first chain, from N to C, is as follows: [VH2]-[connector 1]-[Obscurin-O chain]-[connector 2]-[Fc1].

[0175] The first light chain, from the N end to the C end, is as follows: [VL2] - [connector 3] - [Titin-T chain].

[0176] The second chain, from the N end to the C end, is as follows: [VH1]-[connector 4]-[CH1]-[connector 5]-[VH1]-[connector 6]-[CH1]-[connector 7]-[Fc2].

[0177] The second light chain, from the N end to the C end, is as follows: [VL1]-[connector 8]-[CL];

[0178] or,

[0179] The first chain, from N to C, is as follows: [VH1] - [connector 1] - [Obscurin-O chain] - [connector 2] - [Fc1].

[0180] The first light chain, from the N end to the C end, is as follows: [VL1] - [connector 3] - [Titin-T chain].

[0181] The second chain, from the N end to the C end, is as follows: [VH2]-[connector 4]-[CH1]-[connector 5]-[VH2]-[connector 6]-[CH1]-[connector 7]-[Fc2].

[0182] The second light chain, from the N end to the C end, is as follows: [VL2]-[connector 8]-[CL];

[0183] Wherein, - represents a peptide bond, and the linkers 1, 2, 3, 4, 5, 6, 7, and 8 may be the same or different, may exist independently or not, and may be independently selected from the linkers disclosed above.

[0184] In some specific implementations, connectors 1 and 3 are GGGGS, connector 5 is GGGGSGGGGS, and connectors 2, 4, 6, 7 and 8 are not present.

[0185] In some specific implementation schemes, the molar ratio of the first heavy chain: the first light chain: the second heavy chain: the second light chain is 1:1:1:2.

[0186] In some embodiments, the GPC3 / TRGV9 binding protein comprises a polypeptide chain selected from any one of (1)-(2):

[0187] (1) A first heavy chain, a second heavy chain and a light chain, wherein the first heavy chain comprises an amino acid sequence as shown in or having at least 80% or at least 90% identity with SEQ ID NO: 48, the second heavy chain comprises an amino acid sequence as shown in or having at least 80% or at least 90% identity with SEQ ID NO: 49 or 50, and the light chain comprises an amino acid sequence as shown in or having at least 80% or at least 90% identity with SEQ ID NO: 51;

[0188] (2) A first heavy chain, a second heavy chain, a first light chain, and a second light chain, wherein the first heavy chain comprises an amino acid sequence as shown in or having at least 80% or at least 90% identity with SEQ ID NO: 52, the first light chain comprises an amino acid sequence as shown in or having at least 80% or at least 90% identity with SEQ ID NO: 53, the second heavy chain comprises an amino acid sequence as shown in or having at least 80% or at least 90% identity with SEQ ID NO: 54, and the second light chain comprises an amino acid sequence as shown in or having at least 80% or at least 90% identity with SEQ ID NO: 55.

[0189] In some embodiments, the aforementioned GPC3 / TRGV9 binding protein is: a protein that specifically binds to GPC3 and γδTCR, or an anti-GPC3 / γδTCR antibody or its antigen-binding fragment; a protein that specifically binds to the γ9 chain of GPC3 and TCR, or an anti-GPC3 / TCR γ9 chain antibody or its antigen-binding fragment; a protein that specifically binds to the variable region (Vγ9) of the γ9 chain of GPC3 and TCR, or an anti-GPC3 / Vγ9TCR antibody or its antigen-binding fragment; a protein that specifically binds to GPC3 and γ9δ2TCR, or an anti-GPC3 / γ9δ2TCR antibody or its antigen-binding fragment; a protein that specifically binds to GPC3 and γ9δ1TCR, or an anti-GPC3 / γ9δ1TCR antibody or its antigen-binding fragment; or a protein that specifically binds to GPC3 and TRGV9, or an anti-GPC3 / TRGV9 antibody or its antigen-binding fragment.

[0190] In some embodiments, the aforementioned GPC3 / TRGV9 binding protein has a function or property selected from at least one of the following:

[0191] (a) EC with ≤10 nM 50 The EC binds to γ9δ2T cells. 50 For example, ≤5nM, ≤4nM, ≤3nM, ≤2nM, ≤1nM, ≤0.5nM, ≤0.2nM, ≤0.1nM. The EC 50 It is obtained through FACS detection, which is a commonly used affinity detection method in the art, such as that described in Embodiment 5 of this disclosure;

[0192] (b) Specifically binds to the γ9 chain of TCR, for example, specifically binds to γ9δ1TCR, specifically binds to γ9δ2TCR;

[0193] (c) γ8 chains that do not bind TCR, for example, those that do not bind γ8δ2TCR;

[0194] (d) The variable region (TRGV9) of the γ9 chain that specifically binds to TCR;

[0195] (e) Specifically binds to VγδCαβ chimeric TCRs, but does not bind to VαβCγδ chimeric TCRs;

[0196] Wherein, (b)-(e) can be obtained by conventional detection methods in the art, such as those described in Embodiment 4 of this disclosure;

[0197] (f) Specifically binds to GPC3 protein or GPC3-positive cells, but does not bind or binds very little to GPC3-negative cells (e.g., PBMCs), for example, using the detection method of Example 8 of this disclosure;

[0198] (g) binds to cynomolgus monkey GPC3 and γ9δ2 proteins;

[0199] (h) Do not block the natural BTN2A / BTN3A-TCR signal, for example, using the detection method of Example 9 of this disclosure;

[0200] (i) Mediating the killing of GPC3-positive tumor cells by γδT cells or mediating the killing of GPC3-positive tumor cells by γδT cells in a GPC3 expression level-dependent manner, for example, using the detection method of Example 10 of this disclosure; mediating the killing of GPC3-positive tumor cells by γδT cells in an effector-to-target-dependent manner, for example, using the detection method of Example 12 of this disclosure; mediating the killing of GPC3-positive tumor cells by γδT cells in a manner with low individual variability, for example, using the detection method of Example 11 of this disclosure;

[0201] (j) During the killing of GPC3-positive tumor cells by γδT cells, less cytokines (such as IFNγ and TNFα) are induced to be released, for example, using the detection method of Example 13 of this disclosure;

[0202] (k) Promote the proliferation of γδT cells in PBMCs, for example, by using the detection method of Example 14 of this disclosure;

[0203] (l) Inhibit the proliferation of GPC3-positive tumor cells in vivo, and / or inhibit the growth of GPC3-positive tumors, and / or eliminate GPC3-positive tumors; mouse in vivo model as described in Example 15 of this disclosure.

[0204] In some implementations, the aforementioned GPC3 / TRGV9 binding protein binds to the K of TRGV9. D The value can be ≤1×10 - 7 M, for example, ≤1×10 -8 M, or ≤1×10 -9 M, or ≤1×10 -10 M.

[0205] In some implementations, the aforementioned GPC3 / TRGV9 binding protein binds to the K of GPC3. D The value can be ≤1×10 - 7 M, for example, ≤1×10 -8 M, or ≤1×10 -9 M, or ≤1×10 -10 M.

[0206] In some embodiments, a protein is provided that binds to or competitively binds to the same TRGV9 and / or GPC3 antigenic epitopes as described above with respect to the GPC3 / TRGV9 binding protein of this disclosure.

[0207] In some embodiments, a protein is provided whose binding to TRGV9 and / or GPC3 is blocked by the aforementioned GPC3 / TRGV9 binding protein of this disclosure.

[0208] In some embodiments, a protein or molecule is provided that comprises any of the GPC3 / TRGV9 binding proteins disclosed herein. The protein or molecule may be a conjugate, coupling compound, or fusion protein formed with other compounds or peptides. For example, the conjugate may contain any detectable label.

[0209] In some implementations, the binding protein provided in this disclosure is any TRGV9 binding protein, GPC3 / TRGV9 binding protein, or GPC3 binding protein described in WO2025103451A. The aforementioned patent sequences, test methods, and test data are incorporated herein by reference in their entirety.

[0210] This disclosure provides a lyophilized formulation obtained by freeze-drying a liquid formulation comprising the pharmaceutical composition.

[0211] This disclosure provides a reconstituted solution obtained by reconstituted the lyophilized preparation with a solvent. In some embodiments, the solvent is water, physiological saline, or glucose.

[0212] In some embodiments, the pharmaceutical composition and reconstituted solution are for intravenous injection, subcutaneous injection, intraperitoneal injection, or intramuscular injection. In some specific embodiments, they are for intravenous or subcutaneous injection.

[0213] This disclosure provides an article comprising a container containing the pharmaceutical composition, the lyophilized formulation, and the reconstituted solution.

[0214] This disclosure provides a method for treating or preventing a disease, comprising administering to a subject in need a therapeutically or preventively effective amount of the pharmaceutical composition, the lyophilized formulation, the reconstituted solution, or the article thereof. In some embodiments, the disease is cancer. In some specific embodiments, the disease is liver cancer or GPC3-positive cancer. Attached Figure Description

[0215] Figure 1 is a schematic diagram of the structure of the anti-GPC3 / γδTCR bispecific antibody.

[0216] Figures 2A to 2D show the FACS binding activity assay results of the anti-GPC3 / γδTCR bispecific antibody with GPC3-positive cells and human γ9δ2T cells. Specifically, Figure 2A shows the binding of the anti-GPC3 / γδTCR bispecific antibody on HepG2 cells; Figure 2B shows the binding of the anti-GPC3 / γδTCR bispecific antibody on DLD-1 cells; Figure 2C shows the binding of the anti-GPC3 / γδTCR bispecific antibody on human γδT cells; and Figure 2D shows the binding of the anti-GPC3 / γδTCR bispecific antibody on PBMCs.

[0217] Figures 3A and 3B show the effects of anti-γδTCR antibodies on the natural BTN2A / BTN3A-TCR signal. Figure 3A shows the effect of SDP01378 on the natural BTN2A / BTN3A-TCR signal; Figure 3B shows the effect of SDP01315 on the natural BTN2A / BTN3A-TCR signal.

[0218] Figures 4A to 4D show the cytotoxic activity of anti-γδTCR antibody against tumor cells with different GPC3 expression levels. Specifically, Figure 4A shows the cytotoxic activity against HepG2 cells, Figure 4B shows the cytotoxic activity against Huh-7 cells, Figure 4C shows the cytotoxic activity against MKN-45 cells, and Figure 4D shows the cytotoxic activity against DLD-1 cells.

[0219] Figures 5A to 5D show the cytotoxic activity of γδT cells from different donor sources against HepG2. The γδT cells used in Figures 5A-5D were derived from the induced expansion of donors #SC12004, #SC12392, #XC11053, and #XC11061, respectively.

[0220] Figures 6A to 6C show the killing results of anti-GPC3 / γδTCR bispecific antibodies on tumor cells with low antigen expression at different effector-to-target ratios. Among them, the effector-to-target ratio in Figure 6A is 1:1, the effector-to-target ratio in Figure 6B is 10:1, and the effector-to-target ratio in Figure 6C is 30:1.

[0221] Figures 7A to 7D show the results of increasing the proportion of γδT cells in PBMCs to enhance their cytotoxic activity. Figure 7A shows the cytotoxic activity of donor #XC11053 PBMCs; Figure 7B shows the cytotoxic activity of donor #XC11053 with 30% γδT cells incorporated; Figure 7C shows the cytotoxic activity of donor #SC12392 PBMCs; Figure 7D shows the cytotoxic activity of donor #SC12392 with 30% γδT cells incorporated.

[0222] Figures 8A to 8D show the results of cytokine release detection. Figures 8A-8B show the release of IFNγ and TNFα during the killing of donor #XC11053, respectively; Figures 8C-8D show the release of IFNγ and TNFα during the killing of donor #SC12392, respectively.

[0223] Figure 9 shows the results of detecting the proliferation of γδT cells in PBMCs promoted by the anti-GPC3 / γδTCR bispecific antibody.

[0224] Figures 10A and 10B show the antitumor activity of SDP01716 in the Huh-7 xenograft model, where Figure 10A shows the change in mouse tumor volume and Figure 10B shows the change in mouse body weight.

[0225] Figures 11A and 11B show the antitumor activity of different anti-GPC3 / γδTCR bispecific antibodies in the Huh-7 xenograft model, where Figure 11A shows the change in mouse tumor volume and Figure 11B shows the change in mouse body weight. Detailed Implementation

[0226] definition

[0227] To facilitate understanding of this disclosure, certain technical and scientific terms are specifically defined below. Unless otherwise expressly defined elsewhere in this disclosure, all other technical and scientific terms used in this disclosure shall have the meaning commonly understood by one of ordinary skill in the art to which this disclosure pertains.

[0228] "Buffer" refers to a buffer that is resistant to pH changes through the action of its acid-base conjugate components. Examples of buffers that maintain pH within an appropriate range include acetate, succinate, gluconate, histidine, oxalate, lactate, phosphate, citrate, tartrate, fumarate, glycylglycine, and other organic acid buffers.

[0229] "Histidine buffer" is a buffer containing histidine ions. Examples of histidine buffers include acetate-histidine, succinate-histidine, histidine-histidine hydrochloride, hydrochloride-histidine, sulfate-histidine, and other buffers. For example, a histidine-hydrochloride buffer is prepared by reacting histidine with hydrochloric acid or histidine with histidine hydrochloride.

[0230] "Pharmaceutical composition" means a mixture containing one or more of the compounds described herein or their physiologically / pharmacologically acceptable salts or prodrugs, along with other chemical components, such as physiologically / pharmacologically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to a living organism, thereby promoting the absorption of the active ingredient and its biological activity. In this document, "pharmaceutical composition" and "formulation" are not mutually exclusive.

[0231] Unless otherwise specified, the solvent in the solution form of the pharmaceutical compositions described in this disclosure is water.

[0232] As used herein, the term "about" means a numerical value within the acceptable margin of error of a specific value as determined by one of ordinary skill in the art, the numerical value depending in part on how it is measured or determined (i.e., the limits of the measurement system). For example, in every practice in the art, "about" may mean within or above 1 standard deviation. Alternatively, "about" or "substantially includes" may mean a range of up to 10%. Furthermore, particularly for biological systems or processes, the term may mean up to an order of magnitude or up to five times the numerical value. Unless otherwise stated, when a specific value appears in this application and claims, the meaning of "about" or "substantially includes" should be assumed to be within the acceptable margin of error of that specific value.

[0233] The pharmaceutical compositions described in this disclosure achieve a stable effect: the antibodies therein substantially retain their physical and / or chemical stability and / or biological activity after storage; preferably, the pharmaceutical compositions substantially retain their physical and chemical stability and their biological activity after storage. The storage period is generally selected based on the intended shelf life of the pharmaceutical composition. Currently, various analytical techniques are available for measuring protein stability, which can measure stability after storage at a selected temperature for a selected period of time.

[0234] Stable drug antibody formulations are those in which no significant changes are observed when stored at refrigerated temperatures (2-8°C) for at least 3 months, preferably 6 months, more preferably 1 year, and even more preferably up to 2 years. Additionally, stable liquid formulations include those that exhibit the desired characteristics after storage at 25°C for 1 month, 3 months, 6 months, or at 40°C for 1 month. Typical acceptable criteria for stability are as follows: degradation of antibody monomers typically not exceeding about 10%, preferably not exceeding about 5%, as determined by SEC-HPLC. Visually, the drug antibody formulation is colorless to yellow, clear to slightly opalescent. The concentration, pH, and osmotic pressure of the formulation exhibit variations not exceeding ±10%. Truncation typically not exceeding about 10%, preferably not exceeding about 5%, and aggregation typically not exceeding about 10%, preferably not exceeding about 5%, are observed.

[0235] If, after visual inspection of color and / or clarity, or by means of UV light scattering, size exclusion chromatography (SEC), and dynamic light scattering (DLS), the antibody does not show significant increase in aggregation, precipitation, and / or denaturation, then the antibody “retains its physical stability” in the pharmaceutical formulation. Changes in protein conformation can be evaluated by fluorescence spectroscopy (which determines the tertiary structure of the protein) and by FTIR spectroscopy (which determines the secondary structure of the protein).

[0236] If an antibody does not show significant chemical changes, then the antibody "retains its chemical stability" in the pharmaceutical formulation. Chemical stability can be assessed by detecting and quantifying the chemically altered form of the protein. Degradation processes that frequently alter the chemical structure of a protein include hydrolysis or truncation (evaluated by methods such as size exclusion chromatography and SDS-PAGE), oxidation (evaluated by methods such as peptide mapping combined with mass spectrometry or MALDI / TOF / MS), deamidation (evaluated by methods such as ion exchange chromatography, capillary isoelectric focusing, peptide mapping, and isofpartate measurement), and isomerization (evaluated by measuring isofpartate content, peptide mapping, etc.).

[0237] If the antibody's biological activity at a given time is within a predetermined range of the biological activity exhibited when the pharmaceutical formulation is prepared, then the antibody "retains its biological activity" in the pharmaceutical formulation. The biological activity of an antibody can be determined, for example, by an antigen-binding assay.

[0238] The three-letter and single-letter codes for amino acids used in this disclosure are as described in J. Biol. Chem., 243, p3558 (1968).

[0239] "TRGV9" refers to a polypeptide that, when expressed on the surface of γδT cells, can form a T cell receptor. γδT cells expressing TRGV9 are among the earliest T cells to develop in human fetuses and are the major γδT cell subset in the peripheral blood of healthy adults. "TRGV9" includes any TRGV9 variant, isotype, and species homolog that is naturally expressed by cells (including T cells) or that can be expressed on cells transfected with a gene or cDNA encoding the polypeptide. In a specific embodiment, TRGV9 is human TRGV9. An exemplary human TRGV9 amino acid sequence is provided by GenBank accession number NG_001336.2.

[0240] “GPC3” refers to Glypican 3, a phosphatidylinositol proteoglycan 3, which is anchored to the cell membrane via phosphatidylinositol and is a marker for hepatocellular carcinoma. An exemplary amino acid sequence of human GPC3 is provided by uniprot accession number P51654.

[0241] The term "TRGV9 binding protein" encompasses any protein capable of specifically binding TRGV9 or any molecule containing said protein, including but not limited to antibodies against TRGV9 as defined herein, their antigen-binding fragments, or fusion proteins thereof. In some embodiments, the "TRGV9 binding protein" may contain at least one (e.g., 1, 2, 3, 4, 5, 6, or more) single-domain antibodies or VHHs that specifically bind TRGV9 in embodiments of this disclosure. In some embodiments, the "TRGV9 binding protein" may contain at least one (e.g., 1, 2, 3, 4, 5, 6, or more) VH and VL combinations that specifically bind TRGV9 in embodiments of this disclosure. In some embodiments, the "TRGV9 binding protein" of this disclosure, in addition to containing a single immunoglobulin variable domain of TRGV9 or a VH and VL combination, may also contain a linker and / or a portion having effector function, such as a half-life extension portion (e.g., a single immunoglobulin variable domain binding serum albumin) and / or a fusion partner (e.g., serum albumin) and / or a conjugated polymer (e.g., PEG) and / or an Fc region. In some implementations, "TRGV9 binding protein" encompasses the anti-γδTCR antibody or its antigen-binding fragment in the embodiments of this disclosure.

[0242] "GPC3 / TRGV9 binding protein" encompasses any protein capable of specifically binding to GPC3 and TRGV9, or any molecule containing said protein, including but not limited to antibodies, peptides, fusion proteins of antibodies and peptides, or conjugates thereof. In some embodiments, "GPC3 / TRGV9 binding protein" encompasses the anti-GPC3 / γδTCR bispecific antibody described in the embodiments of this disclosure.

[0243] The term "antibody" encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), full-length antibodies, and antibody fragments (or antigen-binding fragments, or antigen-binding portions), as long as they exhibit the desired antigen-binding activity. Antibodies can refer to immunoglobulins, which are tetrapeptide chains composed of two heavy chains and two light chains linked by interchain disulfide bonds. The amino acid composition and sequence of the constant region of the heavy chain of immunoglobulins differ, thus their antigenicity also differs. Based on this, immunoglobulins can be divided into five classes, or isotypes of immunoglobulins: IgM, IgD, IgG, IgA, and IgE, with their corresponding heavy chains being μ, δ, γ, α, and ε chains, respectively. Within the same class of Ig, based on differences in the amino acid composition of the hinge region and the number and position of disulfide bonds in the heavy chain, different subclasses can be distinguished; for example, IgG can be divided into IgG1, IgG2, IgG3, and IgG4. Light chains are classified into κ chains or λ chains based on differences in their constant regions. Each of the five classes of Ig can have either a κ chain or a λ chain. The sequence of approximately 110 amino acids near the N-terminus of the antibody heavy and light chains varies considerably, forming the variable region (V region); the remaining amino acid sequences near the C-terminus are relatively stable, forming the constant region (C region). The variable region includes three hypervariable regions (HVR) and four relatively conserved framework regions (FR). The three hypervariable regions determine the antibody's specificity and are also known as complementarity-determining regions (CDR). Each light chain variable region (VL) and heavy chain variable region (VH) consists of three CDR regions and four FR regions, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The three CDR regions of the light chain refer to LCDR1, LCDR2, and LCDR3; the three CDR regions of the heavy chain refer to HCDR1, HCDR2, and HCDR3.

[0244] The antibodies disclosed herein can be polyclonal, monoclonal, xenogeneic, allogeneic, syngeneic, or modified forms thereof, with monoclonal antibodies being particularly suitable in many embodiments. Generally, the antibodies disclosed herein are recombinant antibodies. As used herein, “recombinant” refers to products such as cells or nucleic acids, proteins, or vectors, indicating that said cells, nucleic acids, proteins, or vectors have been modified by introducing heterologous nucleic acids or proteins or by altering native nucleic acids or proteins, or that said cells are derived from such modified cells. For example, recombinant cells express genes not present in native (non-recombinant) cell forms or express native genes that are abnormally expressed, poorly expressed, or not expressed at all.

[0245] The determination or definition of a CDR can be accomplished by resolving the structure of the antibody and / or the structure of the antibody-ligand complex, thereby enabling the definitive depiction of the CDR and the identification of residues containing the antibody binding site. This can be achieved using any of the various techniques known to those skilled in the art, such as X-ray crystallography. A variety of analytical methods can be used to identify CDRs, including but not limited to the Kabat numbering system, the Chothia numbering system, the AbM numbering system, the IMGT numbering system, contact definition, and conformation definition. The Kabat numbering system is the standard for numbering residues in antibodies and is commonly used to identify CDR regions (see, for example, Johnson & Wu, 2000, Nucleic Acids Res., 28: 214-8). The Chothia numbering system is similar to the Kabat numbering system, but it takes into account the location of certain structural loop regions (see, for example, Chothia et al., 1986, J. Mol. Biol., 196: 901-17; Chothia et al., 1989, Nature, 342: 877-83). The AbM numbering system uses a computer program integration suite produced by the Oxford Molecular Group to model antibody structures (see, for example, Martin et al., 1989, ProcNatl Acad Sci (USA), 86: 9268-9272; "AbMTM, A Computer Program for Modeling Variable Regions of Antibodies," Oxford, UK; Oxford Molecular, Ltd). The AbM numbering system uses a combination of knowledge databases and a de novo approach to model the tertiary structure of antibodies from basic sequences (see those described in Samudrala et al., 1999, "Ab Initio Protein Structure Prediction Using a Combined Hierarchical Approach" in PROTEINS, Structural, Function and Genetics Suppl., 3: 194-198). Contact definitions are based on the analysis of available complex crystal structures (see, for example, MacCallum et al., 1996, J. Mol. Biol., 5: 732-45). In the conformational definition, the position of CDR can be identified as a residue that contributes enthalpy to antigen binding (see, for example, Makabe et al., 2008, Journal of Biological Chemistry, 283: 1156-1166).Other CDR boundary definitions may not strictly follow one of the methods described above, but still overlap with at least a portion of the Kabat CDR, although they may be shortened or lengthened depending on the predicted or experimental results that a particular residue or group of residues does not significantly affect antigen binding. As used in this disclosure, a CDR may refer to a CDR defined by any method (including combinations of methods) known in the art. The correspondence between various numbering systems is well known to those skilled in the art.

[0246] Those skilled in the art will understand that although a particular numbering system (such as Kabat) is used in a specific embodiment or in a specific SEQ ID NO, those skilled in the art can determine the sequence corresponding to the sequence under other numbering systems, and such sequences are still considered to fall within the scope of this disclosure.

[0247] A "domain" of a polypeptide or protein refers to a folded protein structure that can maintain its tertiary structure independently of the rest of the protein. Generally, a domain is responsible for a single functional property of a protein and, in many cases, can be added to, removed from, or transferred to other proteins without losing the function of the rest of the protein and / or the domain itself.

[0248] An "immunoglobulin domain" refers to a globular region of an antibody chain (such as the chain of a conventional tetrapeptide chain antibody or a heavy chain antibody), or a polypeptide that is essentially composed of such globular regions. The immunoglobulin domain is characterized by its ability to maintain the immunoglobulin folding characteristics of the antibody molecule.

[0249] The "immunoglobulin variable domain" is essentially composed of four "frame regions" (FR1, FR2, FR3, and FR4, respectively) and three "complementarity-determining regions" (CDR1, CDR2, and CDR3). The general structure or sequence of an immunoglobulin variable domain can be represented as: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The immunoglobulin variable domain confers antigen specificity due to the presence of antigen-binding sites.

[0250] "Antibody framework (FR)" refers to a portion of the variable domain that serves as a scaffold for the antigen-binding loop (CDR).

[0251] "Immunoglobulin single variable domain" is generally used to refer to an immunoglobulin variable domain (which can be a heavy chain or light chain domain, including VH, VHH, or VL domains) that can form a functional antigen-binding site without interacting with other variable domains (e.g., without the VH / VL interaction required between the VH and VL domains of a conventional four-chain monoclonal antibody). Examples of "immunoglobulin single variable domain" include nanobodies (including VHH, humanized VHH, and / or camelified VH, such as camelified human VH), IgNAR, domains, and (single-domain) antibodies (such as dAbs) that are VH domains or derived from VH domains. TM ) and antibodies that are VL domains or derived from VL domains (such as dAbs) TM Immunoglobulin single variable domains based on and / or derived from heavy chain variable domains (such as VH or VHH domains) are generally preferred. A specific example of an immunoglobulin single variable domain is the “VHH domain” (or simply “VHH”) as defined below.

[0252] "VHH" is also known as heavy chain single-domain antibody, VHH, V H The H domain, VHH antibody fragment, VHH antibody, and nanobody are variable domains of antigen-binding immunoglobulins called "heavy chain antibodies" (i.e., "antibodies lacking light chains") (Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R.: "Naturally occurring antibodies devoid of light chains"; Nature 363, 446-448 (1993)). The term "VHH" is used to distinguish these variable domains from the heavy chain variable domains (referred to herein as "VH domains" or VH) and light chain variable domains (referred herein as "VL domains" or VL) present in conventional tetrapeptide chain antibody structures. The VHH domain specifically binds to epitopes without the need for other antigen-binding domains; this binding behavior differs from the VH or VL domains in conventional tetrapeptide chain antibodies, where the VL domain recognizes the epitope together with the VH domain. The VHH domain is a small, stable, and highly efficient antigen-recognition unit formed by a single immunoglobulin domain. Terms include "heavy chain single-domain antibody," "VHH domain," "VHH," and "V..." H "H domain", "VHH antibody fragment", "VHH antibody", as well as" The term "domain" ("Nanobody" is a trademark of Ablynx NV, Ghent, Belgium) is used interchangeably. VHHs include, but are not limited to, naturally occurring antibodies produced by camelids, or antibodies produced by camelids that have been humanized, or those obtained through phage display technology. The total number of amino acid residues in a VHH will typically be in the range of 110 to 120, often between 112 and 115. However, it should be noted that smaller and longer sequences may also be suitable for the purposes described in this disclosure. Methods for obtaining VHHs that bind to specific antigens or epitopes have previously been disclosed in the following literature: R. van der Linden et al., Journal of Immunological Methods, 240(2000)185-195; Li et al., J Biol Chem., 287(2012)13713-13721; Deffar et al., African Journal of Biotechnology Vol.8(12), pp.2645-2652, 17 June, 2009 and WO94 / 04678.

[0253] As is known in the art regarding VH and VHH domains, the total number of amino acid residues in each CDR may differ and may not correspond to the total number of amino acid residues indicated by the Kabat number (i.e., one or more positions according to the Kabat number may not be occupied in the actual sequence, or the actual sequence may contain more amino acid residues than allowed by the Kabat number). This means that, in general, the Kabat number may or may not correspond to the actual number of amino acid residues in the actual sequence. Other numbering systems or encoding rules include Chothia, IMGT, and AbM.

[0254] "Humanized antibody," also known as CDR-grafted antibody, refers to an antibody generated by grafting a non-human CDR sequence into the variable region framework of a human antibody. This can overcome the strong immune response induced by chimeric antibodies due to the presence of a large number of non-human protein components. To avoid a decrease in activity along with a decrease in immunogenicity, the variable region of the fully human antibody can be minimally reverse-mutated to maintain activity. Examples of "humanization" include the substitution of a VHH domain derived from camelids with one or more amino acid residues in the original VHH sequence by replacing one or more amino acid residues present at the corresponding position in the VH domain of a conventional human tetrapeptide chain antibody (also referred to herein as "sequence optimization"; in addition to humanization, "sequence optimization" may also encompass other modifications to the sequence by providing one or more mutations that enhance the properties of the VHH, such as removing potential post-translational modification sites). The humanized VHH domain may contain one or more fully human framework region sequences, and in some specific embodiments, may contain the human framework region sequence of IGHV3. Humanization methods include protein surface amino acid resurfacing and antibody humanization using universal framework grafting (CDR grafting to universal framework), which involves "grafting" the CDR onto other "scaffolds" (including but not limited to human scaffolds or non-immunoglobulin scaffolds). Suitable scaffolds and techniques for CDR grafting are known in the art. Germline DNA sequences of human heavy and light chain variable region genes, for example, can be found in the VBase human germline sequence database and in Kabat, EA et al., 1991, Sequences of Proteins of Immunological Interest, 5th edition. The humanized antibodies disclosed herein also include humanized antibodies further matured by phage display with affinity for the CDR. Furthermore, to avoid a decrease in activity along with a decrease in immunogenicity, minimal reverse or reversion mutations can be performed on the human antibody variable region framework sequence to maintain activity.

[0255] "Affinity-matured" antibodies are those that have one or more alterations in one or more hypervariable regions (HVRs) compared to parental antibodies that do not possess such alterations, resulting in improved affinity of the antibody for the antigen. For example, an "affinity-matured" TRGV9 binding protein or anti-TRGV9 antibody has one or more alterations in one or more CDRs that result in increased affinity for the antigen compared to its parent antibody. Affinity-matured antibodies can be prepared, for example, by methods known in the art as described below: Marks et al., 1992, Biotechnology 10: 779-783 or Barbas et al., 1994, Proc. Nat. Acad. Sci, USA 91: 3809-3813; Shier et al., 1995, Gene 169: 147-155; Yelton et al., 1995, Immunol. 155: 1994-2004; Jackson et al., 1995, J. Immunol. 154(7): 3310-9; and Hawkins et al., 1992, J. MoI. Biol. 226(3): 889896; KS Johnson and RE Hawkins, “Affinity maturation of antibodies using phage display”, Oxford University Press 1996.

[0256] Typically, the GPC3 / TRGV9 binding protein and TRGV9 binding protein of this disclosure will be measured in preferred 10 as in Biacore, KinExA, or Fortibio assays. -7 Up to 10 -10 mol / L (M), more preferably 10 -8 Up to 10 -10 moles per liter, or even more preferably 10 -9 Up to 10 -10 or a lower dissociation constant (K) D ), and / or at least 10 - 7 M, preferably at least 10 -8 M, more preferably at least 10 -9 M, more preferably at least 10 -10 The association constant (KA) of M binds to the antigen or target protein it wishes to bind to (i.e., GPC3, TRGV9). Any protein greater than 10... -4 M of K DValues ​​are generally considered to indicate nonspecific binding. The specific binding of antigen-binding proteins to antigens or epitopes can be determined in any suitable manner known, including, for example, surface plasmon resonance (SPR) assays, Scatchard assays, and / or competitive binding assays (e.g., radioimmunoassay (RIA), enzyme immunoassay (EIA), and sandwich competitive assays) as described in this disclosure.

[0257] "Binding affinity" or "affinity" is used in this disclosure as a measure of the strength of a non-covalent interaction between two molecules (e.g., an antibody or a portion thereof with an antigen). The binding affinity between two molecules can be determined by determining the dissociation constant (K). D Quantification can be achieved by using methods such as surface plasmon resonance (SPR) (Biacore) to measure the kinetics of complex formation and dissociation. D The rate constants corresponding to the binding and dissociation of monovalent complexes are called the binding rate constant ka (or kon) and the dissociation rate constant kd (or koff), respectively. D Through equation K D =kd / ka is related to ka and kd. The value of the dissociation constant can be determined directly by well-known methods, and even for complex mixtures, it can be calculated using methods such as those described by Caceci et al. (1984, Byte 9: 340-362). For example, K can be determined using a double-filtered nitrocellulose filter combined with determinations such as those disclosed in Wong & Lohman (1993, Proc. Natl. Acad. Sci. USA 90: 5428-5432). D Other standard assays for assessing the binding ability of antibodies to target antigens are known in the art, including, for example, ELISA, Western blotting, RIA, and flow cytometry, as well as other assays exemplified elsewhere in this disclosure. Antibody binding kinetics and binding affinity can also be determined using standard assays known in the art, such as surface plasmon resonance (SPR), for example, by using Biacore. TM Evaluation can be performed using a system or KinExA. The Kelvin values ​​of individual antibody / antigen complexes can be compared. D The binding affinity is used to compare the binding affinity of different molecules associated with their interactions, for example, comparing the binding affinity of different antibodies for a given antigen. Similarly, the specificity of an interaction can be determined and compared by identifying and comparing the K-value of the target interaction (e.g., the specific interaction between an antibody and an antigen). D Values ​​of K for non-target interactions (e.g., control antibodies known not to bind IGF-1R or TRGV9) D The value is evaluated.

[0258] "Conservative substitution" refers to the substitution with another amino acid residue that has properties similar to the original amino acid residue. For example, lysine, arginine, and histidine have similar properties in that they have basic side chains, and aspartic acid and glutamic acid have similar properties in that they have acidic side chains. Furthermore, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, and tryptophan have similar properties in that they have uncharged polar side chains, and alanine, valine, leucine, threonine, isoleucine, proline, phenylalanine, and methionine have similar properties in that they have nonpolar side chains. Additionally, tyrosine, phenylalanine, tryptophan, and histidine have similar properties in that they have aromatic side chains. Therefore, it will be apparent to those skilled in the art that even when amino acid residues in the group exhibiting similar properties as described above are substituted, it will not show a specific change in properties.

[0259] "Homology," "identity," or "sequence identity" refers to the sequence similarity between two polynucleotide sequences or two polypeptides. When positions in two compared sequences are occupied by the same nucleotide or amino acid monomer—for example, if every position in two DNA molecules is occupied by the same nucleotide—then the molecules are homologous at that position. The percentage of homology between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared multiplied by 100%. For example, at optimal sequence alignment, if six out of ten positions in two sequences match or are homologous, then the two sequences are 60% homologous. Generally, comparisons are made when the highest percentage of homology is obtained by aligning the two sequences.

[0260] "Titin-T chain" or "T chain" refers to a peptide segment or functional variant of the titin protein containing the titin Ig-like 152 domain, with a length of 78-118 amino acids. The titin-T chain can bind to the obscurin Ig-like 1 domain to form a dimerized complex. The functional variant of the T chain involves mutations in certain amino acids of the wild-type T chain, but still retains the ability to bind to the obscurin Ig-like 1 domain to form a dimerized complex. For example, adding or truncating amino acids of appropriate length at the C-terminus and / or N-terminus of the titin Ig-like 152 domain; adding or truncating 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid residues; for example, adding 5 amino acids (the "KAGIR" amino acids) adjacent to the N-terminus of the titin Ig-like 152 domain in the wild-type titin protein, which still retains the function of associating with the obscurin Ig-like 1 domain to form a complex. Other mutations can also be made to the amino acids in the Titin Ig-like 152 domain, for example, to mutate certain amino acids in order to improve interchain disulfide bonds and enhance the stability of the complex.

[0261] "Obscurin-O chain" or "O chain" refers to a peptide segment of 87-117 amino acids in length on the Obscurin protein containing the Obscurin Ig-like 1 domain, or a functional variant thereof. The Obscurin-O chain can bind to the Titin Ig-like 152 domain to form a dimerizing complex. The functional variant of the Obscurin-O chain is a polypeptide formed by mutating certain amino acids of the wild-type O chain, but still possessing the ability to bind to the Titin Ig-like 152 domain to form a dimerizing complex. For example, adding or truncating amino acids of appropriate length at the C-terminus and / or N-terminus of the Obscurin-O domain, such as adding or truncating 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids; for example, adding 5 amino acids, namely “DQPQF”, adjacent to the N-terminus of the Obscurin Ig-like 1 domain in wild-type Obscurin protein, to the N-terminus of the Obscurin-O domain, while still retaining the function of binding with the Titin Ig-like 152 domain to form a dimerized complex. Other mutations can also be made to certain amino acids in the Obscurin Ig-like 1 domain, for example, to improve interchain disulfide bonds or enhance antibody stability.

[0262] The terms "nucleic acid" and "polynucleotide" are used interchangeably in this disclosure and refer to any single-stranded or double-stranded DNA or RNA molecule, and in the case of a single-stranded molecule, its complementary sequence, preferably double-stranded DNA. When a nucleic acid is placed in a functional relationship with another nucleic acid sequence, the nucleic acid is "effectively linked." For example, if a promoter or enhancer affects the transcription of a coding sequence, then the promoter or enhancer is effectively linked to said coding sequence.

[0263] "Host cell" includes individual cells or cell cultures that may be, or have been, recipients of vectors for incorporating polynucleotide inserts. Host cells include progeny of a single host cell, and progeny may not necessarily be identical to the original parent cell (in morphology or genomic DNA complementation) due to natural, accidental, or intentional mutations. Host cells include cells transfected and / or transformed in vivo with the polynucleotides of this disclosure. "Cell," "cell line," and "cell culture" are used interchangeably, and all such names include their progeny. It should also be understood that, due to intentional or unintentional mutations, all progeny may not be exactly identical in DNA content. This includes mutant progeny with the same function or biological activity as those screened from the originally transformed cells.

[0264] "Inhibit" or "block" are used interchangeably and cover both partial and complete inhibition / blockage. "Inhibit growth" (e.g., involving cells) is intended to include any measurable reduction in cell growth.

[0265] "Giving," "applying," and "treatment," when applied to animals, humans, experimental subjects, cells, tissues, organs, or biological fluids, refer to the contact of an exogenous drug, therapeutic agent, diagnostic agent, or composition with the animal, human, subject, cell, tissue, organ, or biological fluid, such as in therapeutic, pharmacokinetic, diagnostic, research, and experimental methods. Cellular treatment includes contact between a reagent and a cell, as well as contact between a reagent and a fluid, wherein the fluid is in contact with the cell. "Giving," "applying," and "treatment" also mean treatment, such as of cells, by means of a reagent, diagnostic agent, conjugate composition, or by means of another cell in vitro and ex vivo. When applied to humans, veterinary, or research subjects, it refers to therapeutic treatment, preventative or prophylactic measures, research, and diagnostic applications.

[0266] "Treatment" means administering, either internally or externally, a therapeutic agent, such as a pharmaceutical composition comprising any of the binding proteins of this disclosure or thereof, to a subject who has, is suspected of having, or is predisposed to having one or more proliferative diseases or their symptoms, and the therapeutic agent is known to have a therapeutic effect on these symptoms. Typically, the therapeutic agent is administered in a treated subject or population in an amount that effectively relieves symptoms of one or more diseases, whether by inducing the regression of such symptoms or inhibiting their development to any clinically measurable degree. The amount of therapeutic agent that effectively relieves symptoms of any specific disease (also referred to as the "therapeuticly effective amount") can vary depending on a variety of factors, such as the subject's disease state, age, and weight, and the drug's ability to produce the desired therapeutic effect in the subject. Whether the disease symptoms have been relieved can be evaluated using any clinical test method commonly used by a physician or other healthcare professional to assess the severity or progression of the symptoms. Although the embodiments of this disclosure (e.g., treatment methods or products) may be ineffective in alleviating the symptoms of the target disease in a particular subject, they should reduce the symptoms of the target disease in a statistically significant number of subjects, as determined by any statistical test known in the art, such as the Student t-test, chi-square test, U-test according to Mann and Whitney, Kruskal-Wallis test (H-test), Jonckheere-Terpstra test, and Wilcoxon test.

[0267] "Effective amount" includes an amount sufficient to improve or prevent the symptoms or condition of a medical condition. Effective amount also means an amount sufficient to allow or facilitate diagnosis. The effective amount used on a subject may vary depending on factors such as the condition to be treated, the subject's overall health, the route and dosage of administration, and the severity of side effects. Effective amount may be the maximum dose or administration regimen that avoids significant side effects or toxicity. Subjects in this disclosure may be animal or human subjects.

[0268] The terms “optional” or “optionally” mean that the event or circumstance described below may, but does not necessarily, occur, and the description includes the possibility that the event or circumstance may or may not occur. “And / or” should be interpreted as specifically disclosing that each of the two specified features or components has or does not have the other. Therefore, the term “and / or” as used in phrases such as “A and / or B” in this disclosure includes “A and B,” “A or B,” “A” (alone) and “B” (alone). Unless the context clearly requires otherwise, throughout the specification and claims, the words “comprising,” “having,” “including,” etc., should be understood to have an inclusive meaning rather than an exclusive or exhaustive meaning; that is, the meaning of “including but not limited to.” In the context of mutations contained in the Fc region in this disclosure, “ / ” means “and,” for example, “354C / 366W” means “354C and 366W,” that is, the Fc region contains the 354C and 366W mutations; the amino acid positions of the mutations in the Fc region of this disclosure are numbered according to the EU numbering system.

[0269] In this disclosure, "subject" and "patient" refer to mammals, especially primates, and particularly humans.

[0270] Example

[0271] The following embodiments are used to further describe this disclosure, but these embodiments are not intended to limit the scope of this disclosure.

[0272] Experimental methods not specifically described in the embodiments or test examples of this disclosure are generally performed under conventional conditions or as recommended by the raw material or product manufacturer. See Sambrook et al., Molecular Cloning, Laboratory Manual, Cold Spring Harbor Laboratory; Methods in Modern Molecular Biology, Ausubel et al., Greene Publishing Association, Wiley Interscience, NY. Reagents not specifically named are commercially available, conventional reagents.

[0273] Example 1. Design and preparation of antigens

[0274] The TCR (γδT cell receptor) on the surface of γδT cells is a heterodimeric membrane protein formed by the complex of γ and δ chains. Amino acids 1-242 of the γ9 chain (Protein data bank, 1HXM, chain B) of the human γδTCR extracellular region were selected, with a 3C restriction enzyme site, a leucine zipper, and a FLAG tag added sequentially to the C-terminus. Amino acids 1-229 of the δ2 ​​chain (Protein data bank, 1HXM, chain A) of the human γδTCR extracellular region were selected, with a 3C restriction enzyme site, a leucine zipper, and a His8 tag added sequentially to the C-terminus. Furthermore, Q180C and V168C mutations were introduced into the constant regions of the γ and δ chains, respectively, to form interchain disulfide bonds.

[0275] The recombinant monkey (Macaca mulatta) γ9δ2TCR protein was obtained by selecting amino acids 1-241 of the monkey γ9 chain (sequence of which can be found in US2019144540A1 SEQ ID NO: 42), with a 3C restriction site, a leucine zipper, and a FLAG tag added sequentially to the C-terminus; amino acids 1-229 of the monkey δ2 chain (sequence of which can be found in US20190144540A1 SEQ ID NO: 37) were selected, with a 3C restriction site, a leucine zipper, and a His8 tag added sequentially to the C-terminus; in addition, Q179C and V168C mutations were introduced into the constant regions of the γ and δ chains, respectively, to form interchain disulfide bonds.

[0276] Recombinant human γ9 chain

[0277] Recombinant human δ2 chain

[0278] >Recombinant monkey γ9 chain

[0279] >Recombinant monkey δ2 chain

[0280] Plasmids carrying the target protein encoding gene were synthesized separately. Human γ9 chain (SEQ ID NO: 1) and human δ2 chain (SEQ ID NO: 2) plasmids were mixed in a 1:1 ratio, and monkey γ9 chain (SEQ ID NO: 3) and monkey δ2 chain (SEQ ID NO: 4) plasmids were mixed in a 1:1 ratio. The plasmids were transiently transfected into Expi293 cells (purchased from Thermo) for expression for 7 days. The human γ9δ2TCR protein and monkey γ9δ2TCR protein were isolated and purified, and stored at -80℃ for later use.

[0281] Example 2. Screening of anti-γδTCR antibodies

[0282] 1. Screening of anti-γδTCR single-domain antibodies

[0283] Adult healthy alpacas were immunized with in vitro expanded human γ9δ2T cells as immunogens, and specific antibodies were screened using the recombinant human γ9δ2TCR protein from Example 1 via phage display.

[0284] Specifically, the initial immunization dose was 2E7 cells per alpaca. Three weeks after the initial immunization, a booster immunization was administered at a dose of 2E7 cells per alpaca. Subsequent booster immunizations were administered at 3-week intervals. Serum samples were collected one week after each booster immunization, and antibody titers in the alpaca serum were detected using Protein ELISA and FACS.

[0285] The specific procedure for the Protein ELISA is as follows: Recombinant human γ9δ2TCR protein was diluted to 2 μg / mL with 0.05 M carbonate buffer (pH 9.6), 100 μL / well, and coated overnight at 4°C. The plate was blocked with PBST buffer containing 5% skim milk for 1 hour and washed 3 times. Alpaca serum was serially diluted 1:2000 in blocking buffer, incubated at 37°C for 45 min, and washed 5 times. 100 μL of horseradish peroxidase-labeled goat anti-Alpaca secondary antibody (AlpVHHs, 053-404-005, diluted 1:10000 with PBS) was added to each well, and the plate was incubated at 37°C for 45 min and washed 5 times. Finally, 100 μL of TMB chromogenic solution was added to each well for color development, and 50 μL of stop solution was added after 5 minutes to terminate the reaction. The absorbance was read at 450 nm using a microplate reader.

[0286] The specific FACS detection procedure is as follows: Collect cells and resuspend them to 4E6 / mL. Add serially diluted alpaca serum to 50 μL of cells and incubate at 4°C for 1 hour. Wash twice with 1% BSA / PBS buffer, discard the supernatant, add 1:200 diluted Anti alpaca IgG iFluor647 (AlpVHHs, 053-404-009), and incubate at 4°C in the dark for 45 min. Wash twice with 1% BSA / PBS buffer, resuspend in 200 μL buffer, and then perform FACS detection.

[0287] Tests showed that the serum titer of the immunized alpaca was greater than 128kJ.

[0288] One week after each of the three immunizations, 50 mL of peripheral blood was collected to separate lymphocytes (PBMCs). Total RNA was extracted from the PBMCs using RNAiso Plus reagent to construct a phage library, which yielded a phage library with a titer of 3.08 × E13 cfu / mL.

[0289] Antibodies against recombinant human γ9δ2TCR protein were panned using phage display. Antibodies that cross-binded with monkey γ9δ2TCR protein were identified using ELISA, and their binding activity to in vitro expanded human γ9δ2T cells was determined using FACS. Positive monoclonal single-domain antibodies were screened using the above ELISA and FACS detection methods, and their sequences are shown below.

[0290] SDP01346 Variable Region (Clone No. ac-025)

[0291] Table 1. CDR sequences of anti-human γδTCR single-domain antibodies (Kabat numbering rules)

[0292] 2. Screening of murine anti-γδTCR antibodies

[0293] Human γ9δ2T cells expanded in vitro were used as immunogens to immunize 6-8 week old Balb / c and SJL mice. Specific antibodies were screened using the recombinant human γ9δ2TCR protein from Example 1 via hybridoma fusion.

[0294] Specifically, the initial immunization dose was 1E7 per mouse. Two weeks after the initial immunization, a booster immunization was administered at a dose of 1E7 per mouse. Subsequent booster immunizations were administered at intervals of 2-3 weeks. Serum samples were collected one week after each booster immunization, and antibody activity in mouse serum was detected using Protein ELISA and FACS.

[0295] The specific procedure for the Protein ELISA is as follows: Coat the plate with 1 μg / mL recombinant human γ9δ2TCR protein and incubate overnight at 4°C. Block with PBST buffer containing 1% BSA for 1 hour, and wash three times. In the blocking buffer, serially dilute mouse serum 1:200 three-fold, incubate at 37°C for 1 hour, wash three times, and incubate with a 1:10000 dilution of anti-mouse IgG-Fc-HRP secondary antibody (Sigma, AP127P) for 1 hour. Wash three times with PBST, add 100 μL of TMB chromogenic solution to each well for color development, and terminate the reaction with stop solution after 15 minutes. Read the absorbance at 450 nm using a microplate reader.

[0296] The specific FACS detection procedure is as follows: 1E5 cells per well were seeded, centrifuged, and the supernatant was discarded. Serially diluted mouse serum was added. The cells were incubated at 4°C for 1 hour. After washing twice with 1% BSA / PBS buffer and discarding the supernatant, 1:500 diluted Alexa Flour 488 goat anti-mouse secondary antibody (Jackson immunoresearch.115-545-071) was added, and the cells were incubated at 4°C in the dark for 30 minutes. After washing twice with 1% BSA / PBS buffer, the cells were resuspended in 200 μL of buffer for FACS detection. The titer of the immunized mouse serum was greater than 72900.

[0297] After the final immunization, mice were intraperitoneally injected with 50 μg of recombinant human γ9δ2TCR protein. Four days later, the mice were sacrificed, and their spleens were harvested. Spleen cells were collected by grinding and mixed with mouse myeloma cells SP2 / 0, and electrofusion was performed to obtain hybridoma cells. Positive clones with OD 450nm > 0.2 were subjected to FACS testing, and positive clones with MFI values ​​> 5000 when binding to human γ9δ2T cells were subjected to subcloning. After initial screening and retesting of subclones, mouse anti-γδTCR antibodies were selected using the above ELISA and FACS detection methods. The sequence of SDP01315 (clone number bph-003) is as follows.

[0298] >SDP01315 (clone number bph-003)VH

[0299] >SDP01315 (clone number bph-003)VL

[0300] Table 2. CDR sequences of murine anti-γδTCR antibodies (Kabat numbering rules)

[0301] Example 3. Construction and functional validation of anti-γδTCR chimeric antibody

[0302] 1. Expression of chimeric antibodies

[0303] The single-domain antibody was cloned into the pTT5 vector and transfected into ExpiCHO cells. After 8 days, the cells were centrifuged to remove them, and the cell culture medium was collected and filtered. The harvested cell culture medium was purified using a nickel affinity column (HisTrap excel, GE). The bound antibody was eluted with 300mM imidazole, and the medium was desalted and changed to PBS to obtain the target antibody.

[0304] SDP01346 full length

[0305] The murine antibody was cloned into the pTT5 vector and transfected into ExpiCHO cells. After 8 days, the cells were centrifuged to remove them, and the cell culture medium was collected and filtered. The harvested cell culture medium was purified using a Protein A affinity column (MabSelect SuRe, GE). The bound antibody was eluted with glycine, and the elution buffer was neutralized with 1M Tris and then desalted to obtain the target antibody.

[0306] SDP01315 Heavy Chain Full Length

[0307] SDP01315 Light Chain Full Length

[0308] 2. Binding of chimeric antibodies to γ9δ2 T cells

[0309] The cellular affinity assay for anti-γδTCR single-domain antibodies is performed as follows: Serially diluted antibody molecules are placed in a 1x 10⁻¹ medium... 5 γ9δ2T cells were incubated at 4°C for 1 hour. Excess antibody was washed away, and DyLight 405-AffiniPure Goat Anti-Alpaca IgG, VHH domain antibody (Jackson, Cat#128-475-232) was added. The cells were incubated at 4°C for 30 minutes. After washing away excess antibody, the cells were resuspended in 200 μL of 2% FBS / PBS buffer. The fluorescence signal on the cell surface was read using a Thermo Attune NxT flow cytometer. The results are shown in Table 3.

[0310] The cellular affinity assay for murine anti-γδTCR antibodies was performed as follows: serially diluted antibody molecules were placed in a 1x 10⁻¹ medium... 5 γ9δ2T cells were incubated at 4°C for 1 hour. After washing away excess antibody, mouse-derived Alexa Flour 647-labeled anti-human Fc antibody (Jackson, Cat#209-605-098) was added, and the cells were incubated at 4°C for 30 minutes. After washing away excess antibody, the cells were resuspended in 200 μL of 2% FBS / PBS buffer, and the fluorescence signal on the cell surface was read using a Thermo Attune NxT flow cytometer. The results are shown in Table 3.

[0311] Table 3. Binding ability of anti-γδTCR chimeric antibodies

[0312] The results showed that SDP01346 and SDP01315 had good binding activity on γ9δ2T cells.

[0313] Example 4. Identification of the antigen-binding region of anti-γδTCR antibody

[0314] This embodiment uses a protein-based ELISA to detect the binding region between the anti-γδTCR antibody and the antigen. Using a method similar to that in Example 1, recombinant human γ9δ1TCR protein (dimeric proteins of SEQ ID NO: 1 and SEQ ID NO: 20), human γ8δ2TCR protein (dimeric proteins of SEQ ID NO: 21 and SEQ ID NO: 2), human VγδCαβ chimeric TCR protein (dimeric proteins of SEQ ID NO: 22 and SEQ ID NO: 23), and human VαβCγδ chimeric TCR protein (dimeric proteins of SEQ ID NO: 24 and SEQ ID NO: 25) were prepared.

[0315] The binding activity of anti-γδTCR antibodies to the aforementioned antigens was identified using ELISA to determine the approximate binding region. The specific detection procedure for the Protein ELISA is as follows: 1 μg / mL of recombinant TCR protein was coated onto each well and incubated overnight at 4°C. The plates were then blocked with PBST buffer containing 1% BSA for 1 hour and washed three times. The antibody was diluted to 30 nM with blocking buffer and incubated at 37°C for 1 hour. After washing three times, the plates were incubated with a 1:10000 dilution of anti-mouse IgG-Fc-HRP secondary antibody (Sigma, AP127P) for 1 hour. The plates were washed three times with PBST, and 100 μL TMB chromogenic buffer was added to each well for color development. The reaction was terminated with stop solution after 15 minutes. The absorbance at 450 nm was read using a microplate reader.

[0316] Recombinant human δ1 chain

[0317] Recombinant human γ8 chain

[0318] Recombinant human Vγ9Cβ chain

[0319] Recombinant human Vδ2Cα chain

[0320] Recombinant human Vβ7Cγ chain

[0321] Recombinant human Vα13Cδ chain

[0322] The ELISA results are shown in Table 4. The absorbance values ​​of antibodies SDP01346 and SDP01315 for different antigens are different. Both antibodies bind to the γ9δ1TCR protein but not the γ8δ2TCR protein, indicating that the antibodies bind to the γ9 chain. Both antibodies bind to the VγδCαβ chimeric TCR protein but not the VαβCγδ chimeric TCR, indicating that the antibodies bind to the variable region (V region) of the TCR. In summary, it can be clearly concluded that antibodies SDP01346 and SDP01315 bind to TRGV9.

[0323] Table 4. Identification results of chimeric antibody-antigen binding regions

[0324] Example 5. Humanization of anti-γδTCR antibody

[0325] The variable region sequence was compared with the antibody germline database to obtain human germline templates with high homology. Among them, the human germline heavy chain template used for SDP01346 was IGHV3-30; the human germline heavy chain template used for SDP01315 was IGHV3-21, and the human germline light chain template was IGKV1-12. After predicting the structure of the monoclonal antibody through homology modeling, the VH, VL of the murine antibody or the CDR of the single-domain antibody were chimeric into a suitable human GermLine framework (Bioinformation.2014;10(4):180-186;Methods Mol Biol.2019;1904:213-230), and then a reversion mutation was introduced.

[0326] The obtained humanized molecule sequence is as follows:

[0327] >SDP01346 VH4

[0328] >SDP01315 VH2

[0329] >SDP01315 VL2

[0330] After humanization of single-domain antibodies, full-length antibodies were constructed, with GGGGSHHHHHHH (SEQ ID NO: 29) added after the corresponding VHH. For mouse antibodies, after humanization, full-length antibodies were constructed, using Cκ for the light chain constant region and IgG1 with L234F and L235E mutations for the heavy chain constant region.

[0331] Table 5. Correspondence between antibody names and antibody structures.

[0332] The full-length sequences of SDP01378 and SDP01369 are as follows:

[0333] SDP01378 full length

[0334] SDP01369 Heavy Chain Full Length

[0335] SDP01369 Light Chain Full Length

[0336] The following section describes the FACS assay for the binding of humanized monoclonal antibody to γ9δ2T cells.

[0337] Affinity assay for humanized single-domain antibody SDP01346: The serially diluted antibody molecules were analyzed at 1×10⁻⁶... 5 γ9δ2T cells were incubated at 4°C for 1 hour. After washing away excess antibody, DyLight 405-AffiniPure Goat Anti-Alpaca IgG, VHH domain antibody (Jackson, Cat#128-475-232) was added and incubated at 4°C for 30 minutes. After washing away excess antibody, the cells were resuspended in 200 μL of 2% FBS / PBS buffer and the fluorescence signal on the cell surface was read using a Thermo Attune NxT flow cytometer. The results are shown in Table 6.

[0338] Affinity assay for humanized mouse chimeric antibody SDP01315: The serially diluted antibody molecules were analyzed at 1×10⁻⁶... 5 γ9δ2T cells were incubated at 4°C for 1 hour. After washing away excess antibody, mouse-derived Alexa Flour647-labeled anti-human Fc antibody (Jackson, Cat#209-605-098) was added, and the cells were incubated at 4°C for 30 minutes. After washing away excess antibody, the cells were resuspended in 200 μL of 2% FBS / PBS buffer, and the fluorescence signal on the cell surface was read using a Thermo Attune NxT flow cytometer. The results are shown in Table 6.

[0339] Table 6. Affinity Detection of Humanized Molecules in SDP01346 and SDP01315

[0340] Example 6. Design and preparation of anti-GPC3 / γδTCR bispecific antibody

[0341] Antibody G, selected from the GPC3 end, has nanomolar affinity. The sequences of its heavy and light chain variable regions are shown below. Antibody G binds to the C-terminal subunit and does not bind to soluble GPC3.

[0342] GPC3 VH

[0343] GPC3 VL

[0344] Table 7. VH and VL of Antibody G (Kabat numbering rules)

[0345] We designed several GPC3 / γδTCR dual antibodies, and ultimately selected a 1+1 asymmetric structure with SDP01346 VH4 (i.e., SDP01378), using KIH (knob into hole) to avoid heavy chain mismatch; and a 2+1 asymmetric structure with SDP01315H2L2, using KIH to avoid heavy chain mismatch and HOT to avoid light chain mismatch. A schematic diagram of the structure is shown in Figure 1.

[0346] To prevent and reduce heavy chain and light chain mismatches, Obscurin-O and Titin-T are used (SEQ ID NO: 41-42), and CH1 and Cκ are used (SEQ ID NO: 43-44). Mutations in IgG are used to prevent and reduce mismatches between the two heavy chains. The full-length sequences of the bispecific antibodies are as follows: underlined portions represent CDR sequences; wavy underlined portions represent Obscurin-O or Titin-T sequences; dotted underlined portions represent CH1 or Cκ; italicized portions represent the IgG1 Fc region; bold italicized portions represent point mutations in the Fc region; and bold text represents linkers.

[0347] Obscurin-O

[0348] Titin-T

[0349] CH1

[0350] >Cκ

[0351] >IgG1 Fc(WT)

[0352] >IgG1 Fc1 (mutated to S354C / T366W / L234F / L235E)

[0353] >IgG1 Fc2 (mutated to Y349C / T366S / L368A / Y407V / L234F / L235E)

[0354] >SDP01716 H1

[0355] >SDP01716 H2

[0356] >SDP01716 H2-Fc

[0357] >SDP01716 L

[0358] >SDP01704 H1

[0359] >SDP01704 L1

[0360] >SDP01704 H2

[0361] >SDP01704 L2

[0362] The nucleotide sequence encoding the antibody was cloned into the pTT5 vector and transfected into ExpiCHO cells. After 8 days, the cells were centrifuged to remove the cells, and the cell culture medium was collected and filtered. The harvested cell culture medium was purified using a Protein A affinity column (MabSelect SuRe, GE). The bound antibody was eluted with glycine, and the elution buffer was neutralized with 1M Tris and then desalted. The target antibodies SDP01716 and SDP01704 were obtained by detection.

[0363] Example 7. Detection of the binding affinity between anti-GPC3 / γδTCR bispecific antibody and human and monkey antigens.

[0364] A Protein A biosensor chip (Cat.#29139121-AB, Cytiva) was used. Each antibody was prepared as a ligand using HBS-EP+ buffer to capture Protein A on the chip channels. Human GPC3 (Sino Biological, Cat#10088-H08H) / cynomolgus GPC3 (Acrobiosystems, Cat#GP3-C5225) / human γ9δ2 / cynomolgus γ9δ2 antigens were prepared as analytes using HBS-EP+ buffer and serially diluted 2-fold. The diluted antigens were flowed through the experimental and reference channels at a flow rate of 30 μL / min for 80 seconds for binding and 300 seconds for dissociation. Regeneration buffer was 10 mM Glycine pH 1.5 (GE Healthcare, BR-1003-54) at a flow rate of 10 μL / min for 30 seconds. The data was analyzed using Biacore 8Kevaluation software.

[0365] The results are shown in Tables 8 and 9. The antigen-binding affinity of both antibodies to human and cynomolgus monkey GPC3 proteins was around 2 nM, similar to that of antibody G. The binding affinity of both antibodies to cynomolgus monkey γ9δ2TCR protein was K. D Both are around 50 nM.

[0366] Table 8. Binding kinetics of antibody to human / cynomolgus monkey GPC3 protein

[0367] Table 9. Binding kinetics of antibody to human / cynomolgus monkey γ9δ2 protein

[0368] Example 8. Detection of the binding activity of anti-GPC3 / γδTCR bispecific antibody with GPC3-positive cells and human γ9δ2T cells.

[0369] The binding activity of the γδT bispecific antibody to HepG2 cells (purchased from ATCC) that naturally overexpress human GPC3 and DLD-1 cells (purchased from ATCC) that do not express human GPC3 was detected using FACS assays. The GPC3 binding activity assay of the anti-GPC3 / γδTCR bispecific antibody on cells was performed by detecting the fluorescence signal of the antibody bound to the cell surface; the intensity of the fluorescence signal was used to evaluate the binding strength of the antibody. Specifically, serially diluted antibody molecules and control molecules were mixed at 1 x 10⁻⁶ cells / mL. 5Cells were incubated at 4°C for 1 hour, and excess antibody was washed away. Then, mouse-derived Alexa Flour 647-labeled anti-human Fc antibody (Jackson, Cat#209-605-098) was added, and the cells were incubated at 4°C for 30 minutes. After washing away excess antibody, the cells were resuspended in 200 μL of 2% FBS / PBS buffer. The fluorescence signal on the cell surface was read using a Thermo Attune NxT flow cytometer. The cells used were HepG2 cell lines.

[0370] The binding activity of the anti-GPC3 / γδTCR bispecific antibody to human γ9δ2T cells and human PBMCs was detected using FACS assays. Human γ9δ2T cells were obtained by induction with zoledronic acid and IL-2. The binding activity assay of the anti-GPC3 / γδTCR bispecific antibody on γδT cells was performed by detecting the fluorescence signal of the antibody bound to the cell surface; the intensity of the fluorescence signal was used to evaluate the binding strength of the antibody. Specifically, serially diluted antibody molecules and control molecules were mixed at 1 x 10⁻⁶ cells / mL. 5 Cells were incubated at 4°C for 1 hour, excess antibody was washed away, and mouse-derived Alexa Flour 647-labeled anti-human Fc antibody (Jackson, Cat#209-605-098) was added. After incubation at 4°C for 30 minutes, excess antibody was washed away, and the cells were resuspended in 200 μL of 2% FBS / PBS buffer. The fluorescence signal on the cell surface was read using a Thermo Attune NxT flow cytometer.

[0371] The results are shown in Figures 2A-2D. As shown in Figures 2A and 2B, SDP01716 and SDP01696 exhibit comparable GPC3 end affinity, EC... 50 The concentrations were 4.853 nM and 5.166 nM, respectively. SDP01704 exhibited divalent binding characteristics, EC 50 The affinity of SDP01716 for γ9δ2T cells was 0.9064 nM, that of SDP01696 was 2.676 nM, and that of SDP01704 was 4.289 nM; none of the antibodies tested showed nonspecific binding on GPC3 negative cells. As shown in Figures 2C and 2D, the affinity of SDP01716 for γ9δ2T cells was 0.9064 nM, that of SDP01696 was 2.676 nM, and that of SDP01704 was 4.289 nM; none of the antibodies tested showed nonspecific binding on PBMCs.

[0372] Example 9. Effect of anti-GPC3 / γδTCR bispecific antibody on BTN2A / BTN3A-TCR native signaling

[0373] In its natural state, intracellular phosphorylated antigens bind to BTN3A, altering the molecular tension of BTN3A. Two BTN3A molecules and two BTN2A molecules combine to form a heterotetramer, which then interacts with the TCR, activating the TCR and inducing the activation, proliferation, and killing functions of γδT cells. Since anti-γδTCR antibodies also bind to the TCR, this embodiment evaluates the effect of the disclosed antibody on the native BTN2A / BTN3A-TCR signaling. SDP01378 is the γδT-terminal monovalent molecule of SDP01716, and SDP01315 is a monovalent molecule of SDP01696 and SDP01704.

[0374] A375-Luc cells were cultured in RPMI 1640 medium containing 10% inactivated fetal bovine serum. γδT cells were obtained from PBMC expansion. A375-Luc cell density was adjusted, and cells were seeded at 25 μL / well in 96-well plates, resulting in a cell mass of 1 × 10⁶ cells / well. 4 / well; 25μL / well of γδT cells (1×10⁶) were collected. 5 Mix the sample with A375-Luc; then add 25 μL / well of SDP01378 or SDP01315 (final concentration 10 nM), and 25 μL / well of serially diluted BTN3A agonist antibody. Incubate at 37°C, 5% CO2 for 24 hours. After 24 hours, add 100 μL / well of Bright-Glo™ Luciferase Assay System (Promega, E2650) reagent for detection. Refer to the reagent instructions for specific procedures.

[0375] As shown in Figures 3A and 3B, neither SDP01378 nor SDP01315 blocked the native BTN2A / BTN3A-TCR signal. Therefore, it can be concluded that the anti-GPC3 / γδTCR bispecific antibody of this disclosure does not block the native BTN2A / BTN3A-TCR signal.

[0376] Example 10. Detection of the in vitro γδT cell killing activity against tumor cells mediated by anti-GPC3 / γδTCR bispecific antibody.

[0377] In this embodiment, the lactate dehydrogenase (LDH) assay was used to evaluate the antibody-mediated killing activity of γδT cells against target cells with different GPC3 expression levels.

[0378] HepG2 cells naturally highly express GPC3 and are cultured in DMEM (Gibco, Cat#11995-065, hereinafter the same) containing 15% inactivated fetal bovine serum. Huh-7 cells express moderate levels of GPC3 and are cultured in DMEM. MKN-45 cells express low levels of GPC3 and are cultured in RPMI 1640 (Gibco, Cat#10491A-01, hereinafter the same). DLD-1 cells do not express GPC3 and are cultured in RPMI 1640. Target cells were digested and resuspended in RPMI 1640 medium with 2% serum, and the density was adjusted to 7 × 10⁶ cells / year. 4 Cells / mL; then seeded at 50 μL / well in a 96-well plate, and added 50 μL of serially diluted test antibody. Add 50 μL of culture medium to each well. Collect γδT cells, resuspend in RPMI 1640 containing 2% fetal bovine serum, and adjust cell density. Seed at 50 μL / well in the above experimental plate and incubate at 37°C, 5% CO2 for 24 hours. Remove the cell culture plate, centrifuge (400g, 5 min) to collect the cell culture supernatant, and analyze using CytoTox. The Non-Radioactive Cytotoxicity Assay kit (Promega, G1780) is used to detect LDH levels. Refer to the kit's instruction manual for specific instructions.

[0379] The results, as shown in Figures 4A to 4D and Table 10, indicate that the killing activity of the bispecific antibody against tumor cells decreased with the decrease in antigen expression. The affinity of the antibody γδT-terminus was positively correlated with the killing activity against tumor cells, and the bivalent molecule at the GPC3 terminus was stronger than the monovalent molecule.

[0380] Table 10. Killing effects of anti-GPC3 / γδTCR bispecific antibodies on cells expressing different antigens Note: - indicates that no lethal activity was detected.

[0381] Example 11. Effect of anti-GPC3 / γδTCR bispecific antibody on γδT cell killing from different PBMC donors

[0382] In this embodiment, the lactate dehydrogenase (LDH) assay was used to evaluate the antibody-mediated killing activity of γδT cells against GPC3-expressing target cells.

[0383] HepG2 cells were digested and resuspended in RPMI 1640 medium with 2% serum, and the cell density was adjusted to 7 × 10⁶ cells / year. 4Cells / mL; then seeded at 50 μL / well in a 96-well plate, and 50 μL of serially diluted test antibody was added. 50 μL of culture medium was added to each well. γδT cells expanded from different donors were collected and resuspended in RPMI 1640 containing 2% fetal bovine serum to adjust cell density. 50 μL / well was seeded in the above experimental plate and incubated at 37°C in a 5% CO2 incubator for 24 hours. The cell culture plate was removed, and the cell culture supernatant was collected by centrifugation (400g, 5 minutes) and analyzed using CytoTox. The Non-Radioactive Cytotoxicity Assay Kit (Promega, G1780) was used to detect LDH levels.

[0384] The results of SDP01716 are illustrated exemplarily. As shown in Figures 5A to 5D and Table 11, SDP01716 can mediate the killing of tumor cells by γδT cells from different donors, EC... 50 There is no significant difference in maximum damage.

[0385] Table 11. Antibody-mediated killing activity of γδT cells from different donors against HepG2 cells. Note: #SC12004, #SC12392, #XC11053, and #XC11061 are γδT cells expanded from different donor sources (human peripheral blood from healthy allogeneic individuals), and - indicates no killing effect was detected.

[0386] Example 12. Detection of the killing activity of anti-GPC3 / γδTCR bispecific antibody against cells with low antigen expression at different effector-target ratios.

[0387] In this embodiment, the lactate dehydrogenase (LDH) assay was used to evaluate the antibody-mediated killing activity of γδT cells against GPC3-low expression target cells.

[0388] MKN-45 cells naturally express GPC3 at low levels. After digestion, MKN-45 cells were resuspended in RPMI 1640 medium with 2% serum, and the cell density was adjusted to 7 × 10⁶ cells / year. 4 Cells / mL; then seeded at 50 μL / well in a 96-well plate, and 50 μL of serially diluted test antibody was added to each well. 50 μL of culture medium was added to each well. γδT cells were collected and resuspended in RPMI 1640 containing 2% fetal bovine serum to adjust cell density. 50 μL / well was seeded in the above experimental plate, with final effector-to-target ratios (γδT cells:MKN-45 cells) of 1:1; 10:1; 30:1. Incubated at 37°C in a 5% CO2 incubator for 24 hours. The cell culture plate was removed, and the cell culture supernatant was collected by centrifugation (400g, 5 minutes) using CytoTox. The Non-Radioactive Cytotoxicity Assay kit (Promega, G1780) is used to detect LDH levels. Refer to the kit's instruction manual for specific instructions.

[0389] The results for SDP01716 are illustrated. As shown in Figure 6A, at a low effector-to-target ratio of 1:1, SDP01716 exhibits weak cytotoxic activity against cells with low antigen expression, with a maximum kill rate of 17%. As shown in Figure 6B, increasing the effector-to-target ratio to 10:1 enhances the cytotoxic activity against cells with low antigen expression, achieving a maximum kill rate of 64%. As shown in Figure 6C, when the effector-to-target ratio is increased to 30:1, almost 100% kill is achieved. In other words, the anti-GPC3 / γδTCR bispecific antibody disclosed herein can kill tumor target cells in an effector-to-target ratio-dependent manner.

[0390] Example 13. Enhancing the killing activity of anti-GPC3 / γδTCR bispecific antibody and detecting cytokine release by increasing the proportion of γδT cells in PBMCs.

[0391] In this embodiment, the lactate dehydrogenase (LDH) assay was used to evaluate the antibody-mediated killing activity of γδT cells against GPC3-expressing target cells.

[0392] HepG2 cells naturally highly express GPC3. After digestion, HepG2 cells were resuspended in RPMI 1640 medium with 2% serum, and the cell density was adjusted to 7 × 10⁶ cells / year. 4 Cells / mL; then seeded at 50 μL / well in a 96-well plate, and added 50 μL of serially diluted test antibody. Add 50 μL of culture medium to each well. Collect PBMC cells, resuspend in RPMI 1640 containing 2% fetal bovine serum, and adjust cell density. Seed at 50 μL / well in the above experimental plate; or add 30% γδT cells to PBMCs, seed at 50 μL / well in the above experimental plate, and incubate at 37°C, 5% CO2 for 24 hours. Remove the cell culture plate, centrifuge (400g, 5 min) to collect the cell culture supernatant, and analyze using CytoTox. The Non-Radioactive Cytotoxicity Assay kit (Promega, G1780) was used to detect LDH levels. Simultaneously, the kit was used to detect IFNγ (Cisbio, S62HIFNGPEG) and TNFα (Cisbio, 62HTNFAPEH) to determine the secretion levels of the corresponding cytokines. For specific instructions, please refer to the kit's instruction manual.

[0393] The results of SDP01716 are illustrated exemplarily. The results are shown in Figures 7A to 7D, where Figure 7A shows the cell killing activity of PBMCs from donor #XC11053; Figure 7B shows the cell killing activity of PBMCs from donor #XC11053 incorporating 30% γδT cells; Figure 7C shows the cell killing activity of PBMCs from donor #SC12392; and Figure 7D shows the cell killing activity of PBMCs from donor #SC12392 incorporating 30% γδT cells.

[0394] Figures 7A and 7C illustrate that SDP01716's tumor cell-killing ability in a pure PBMC system is weaker than that of the CD3-targeting bispecific antibody BMK-029 (ERY974 in US20220348658), because the CD3 bispecific antibody can mobilize more T cells as effector cells to kill tumors. Figures 7B and 7D show that increasing the proportion of γδT cells in PBMCs can enhance its killing activity. Meanwhile, the cytokine release detection results corresponding to Figures 7A to 7D are shown in Figures 8A to 8D, indicating that SDP01716 induces less IFNγ and TNFα release when killing tumor cells.

[0395] Example 14. Detection of the activity of anti-GPC3 / γδTCR bispecific antibody in promoting the proliferation of γδT cells in PBMCs

[0396] In this embodiment, flow cytometry was used to evaluate the activity of anti-GPC3 / γδTCR bispecific antibody in inducing γδT cell proliferation in PBMCs.

[0397] Take 800 μL (1×10⁻⁶) of PBMC 6 HepG2 cells were added to 24-well plates; after washing twice with PBS, the cell density was adjusted to 5 × 10⁶ cells / well. 5 Cells / mL, add 1 mL to the corresponding well; prepare the antibody to be tested with the appropriate concentration in culture medium, then add 200 μL to the well. Incubate at 37℃, 5% CO2, changing the medium every 3 days. After 6 to 7 days, wash the cells twice with PBS, and stain with CD3 antibody (BD, Cat#564713), Vδ2TCR antibody (BD, Cat#555739), and Vγ9TCR antibody (BD, Cat#555732) to identify changes in the proportion of γδT cells.

[0398] As shown in Figure 9, after 6-7 days of stimulation, SDP01716, SDP01696 and SDP01704 in PBMC cells derived from the three donors #XC11211, #XC11061 and #XC11251 significantly increased the proportion of γδT cells.

[0399] Example 15. Validation of a mouse model of human liver cancer Huh-7 xenograft.

[0400] 1. Human liver cancer Huh-7 cells (Chinese Academy of Sciences Cell Bank) were used at a concentration of 5 × 10⁻⁶ cells / year. 6 100 μL / mouse was injected subcutaneously into NSG mice (female, 6-8 weeks old, provided by Vital River) and randomly divided into 4 groups (G1-G4) of 7 mice per group. On the day of grouping, tumor cells were injected, and γδT cells and drugs were infused simultaneously. Each group was administered drugs according to the following regimen:

[0401] G1: Medium; G2: γδT cells + PBS

[0402] G3: γδT cells + SDP01716 (3 mg / kg)

[0403] G4: γδT cells + SDP01716 (0.3 mg / kg)

[0404] Subsequently, γδT cells were infused and medication was administered once weekly. Tumor volume was measured twice weekly during the administration and observation period, and the measurements were recorded. The calculation formula is as follows (the same applies below):

[0405] Calculate tumor volume (TV) = 1 / 2 × a × b 2 , where a and b represent the long and short diameters of the tumor, respectively;

[0406] Relative tumor proliferation rate T / C% = (T-T0) / (C-C0) × 100;

[0407] Tumor inhibition rate (TGI%) = 1 - T / C%.

[0408] The results are shown in Figures 10A and 10B and Table 12. The TGI of the γδT cell monotherapy group (G2) was 11%, indicating a limited inhibitory effect on tumor growth. SDP01716 inhibited tumor growth in a dose-dependent manner, with a TGI of 58% at a dose of 3 mpk, and none of the treatment groups had a significant effect on the body weight of mice.

[0409] Table 12. Antitumor activity of SDP01716 in Huh-7 xenograft model Note: * represents P<0.05; ** represents P<0.01.

[0410] 2. Huh-7 cells were cultured at 5 × 10⁻⁶ cells per cell line. 6 100 μL / mouse was injected subcutaneously into NSG mice (female, 6-8 weeks old, provided by Jicui Yaokang) and randomly divided into 6 groups of 7 mice each. On the day of grouping, tumor cells were injected, and γδT cells and drugs were infused simultaneously. Each group was administered drugs according to the following regimen:

[0411] G1: Medium

[0412] G2: γδT cells

[0413] G3: γδT cells + SDP01716 (3 mg / kg)

[0414] G4: γδT cells + SDP01696 (3.9mg / kg)

[0415] G5: γδT cells + SDP01704 (5.1 mg / kg).

[0416] Subsequently, γδT cells were infused and medication was administered once a week. If γδT cells and antibodies were used in combination, they were administered simultaneously. Tumor volume was measured twice a week during the administration and observation period, and the measurements were recorded.

[0417] The results are shown in Figures 11A and 11B and Table 13. The bispecific antibodies disclosed in this invention can effectively inhibit tumors, and no significant changes in body weight were observed in mice in any of the treatment groups.

[0418] Table 13. Antitumor activity of bispecific antibodies in Huh-7 xenograft model Note: ** represents P<0.01.

[0419] The following describes the formulation development of antibody SDP01716, with heavy chain 1 as shown in SEQ ID NO: 48, heavy chain 2 as shown in SEQ ID NO: 50 (H2-Fc), and light chain as shown in SEQ ID NO: 51.

[0420] Example 16. Screening of pH and buffer systems

[0421] Formulations were prepared using 50 mg / mL protein, different pH and buffer systems as shown in Table 14, 75 mg / mL sucrose, 0.02 mg / mL disodium edetate (EDTA-2Na), and 0.4 mg / mL polysorbate 80 (PS80). Forced degradation studies were conducted on the samples (40°C for 4 weeks). Appearance, SEC, NR-CE, and iCIEF were used as evaluation indicators to investigate the effects of different pH and buffer systems on protein stability.

[0422] The equipment, antibodies, and methods used in the preparation and testing of the formulation are as follows:

[0423] (1) SEC size exclusion chromatography: an analytical method for separating solutes based on the relative relationship between the pore size of gel pores and the coil size of polymer sample molecules.

[0424] SEC% (SEC monomer content percentage) = A monomer / A total × 100% (A monomer is the peak area of ​​the main monomer in the sample, and A total is the sum of the peak areas of all peaks). ΔSEC% = SEC% of the formulation before stability test - SEC% of the formulation after stability test.

[0425] Instruments used for SEC determination: Agilent HPLC 1260; Waters UPLC Acquity Premier

[0426] Chromatographic column: Waters, BioResolve TM SEC mAb 2.5μm 7.8×300mm Column; Phenomenex, Biozen 1.8μm dSEC-2, 4.6*150mm,

[0427] (2) NR-CE capillary gel electrophoresis: an electrophoresis method in which a gel is transferred into a capillary as a supporting medium and separated according to the molecular weight of the sample under a certain voltage.

[0428] NR-CE% (NR-CE main peak content percentage) = A main peak / A total × 100% (A main peak is the peak area of ​​the main peak in the sample, and A total is the sum of the areas of all peaks). ΔNR-CE% = NR-CE% of the formulation before stability test - NR-CE% of the formulation after stability test.

[0429] Instrument used for CE testing: SCIEX capillary electrophoresis apparatus, model PA800 plus

[0430] (3) iCIEF imaging capillary isofocusing electrophoresis:

[0431] This technique separates proteins based on their different isoelectric points (pI). iCIEF% (iCIEF main peak content percentage) = main peak area / total area * 100% (total area is the sum of the areas of acidic peaks, main peak, and basic peaks), ΔiCIEF% = iCIEF% of the formulation before stability testing - iCIEF% of the formulation after stability testing. The instrument used for iCIEF determination is manufactured by Protein Simple, model Muarice.

[0432] (4) Instrument for protein concentration determination: UV-Vis spectrophotometer, model: Nano Drop oneC, optical path length: 1mm.

[0433] Table 14. Screening Results of pH and Buffer Systems Note: 40℃ W4: Placed at 40℃ for 4 weeks, the same applies below.

[0434] Example 17. Buffer system concentration screening

[0435] Formulations were prepared using 50 mg / mL protein, histidine-histidine hydrochloride (His-HCl) 5.5 buffer systems at different concentrations as shown in Table 15, 80 mg / mL sucrose, 0.02 mg / mL EDTA-2Na, and 0.4 mg / mL PS80. Forced degradation studies were conducted on the samples (40℃ for 4 weeks). The effects of different concentrations of the His-HCl 5.5 buffer system on protein stability were investigated using SEC, NR-CE, and iCIEF as evaluation indicators.

[0436] The results are shown in Table 15. SEC, NR-CE, and iCIEF data showed that after 4 weeks of storage at 40°C, there were no significant differences among the formulation groups with different concentrations (10–50 mM) of His-HCl 5.5 buffer, and all showed good stability.

[0437] Table 15. Results of Buffer System Concentration Screening

[0438] Example 18. Screening of Surfactant Types

[0439] A formulation was prepared containing 1 mg / mL protein, 20 mM His-HCl, 80 mg / mL sucrose, different types of surfactants as shown in Table 16, 0.02 mg / mL EDTA-2Na, and pH 5.5. Forced degradation studies were conducted on the samples (40°C for 4 weeks), and the effects of different types of surfactants on protein stability were investigated using SEC, NR-CE, and iCIEF as evaluation indicators.

[0440] The results are shown in Table 16. SEC, NR-CE, and iCIEF data showed that after 4 weeks of storage at 40°C, there were no significant differences between the formulations containing PS80 and poloxamer 188 (P188), and all showed good stability.

[0441] Table 16 Results of Surfactant Selection

[0442] Example 19. Surfactant Concentration Screening

[0443] Formulations were prepared containing 50 mg / mL protein, 20 mM His-HCl, 80 mg / mL sucrose, different concentrations of surfactants shown in Table 17, 0.02 mg / mL EDTA-2Na, and pH 5.5. Forced degradation studies were conducted on the samples (40°C for 4 weeks), and the effects of different surfactant concentrations on protein stability were investigated using SEC, NR-CE, and iCIEF as evaluation indicators.

[0444] The results are shown in Table 17. SEC, NR-CE, and iCIEF data showed that after 4 weeks of storage at 40°C, there were no significant differences among the formulation groups with different concentrations of surfactant (0.1–2 mg / mL), and all showed good stability.

[0445] Table 17 Screening results for different surfactant concentrations

[0446] Example 20. Screening of sucrose concentration

[0447] Formulations were prepared with 50 mg / mL protein, 20 mM His-HCl, different concentrations of sucrose as shown in Table 18, 0.4 mg / mL PS80, 0.02 mg / mL EDTA-2Na, and pH 5.5. Forced degradation studies were conducted on the samples (40°C for 4 weeks), and the effects of different sucrose concentrations on protein stability were investigated using SEC, NR-CE, and iCIEF as evaluation indicators.

[0448] The results are shown in Table 18. Data from SEC, NR-CE, and iCIEF showed that after 4 weeks of storage at 40°C, there were no significant differences among the formulation groups with different concentrations of sucrose (30–100 mg / mL), and all showed good stability.

[0449] Table 18 Screening results for different sucrose concentrations

[0450] Example 21. EDTA-2Na Concentration Screening

[0451] Formulations were prepared with 50 mg / mL protein, 20 mM His-HCl, 80 mg / mL sucrose, 0.4 mg / mL PS80, and different concentrations of EDTA-2Na as shown in Table 19, at pH 5.5. Forced degradation studies were conducted on the samples (40°C for 4 weeks), and the effects of different EDTA-2Na concentrations on protein stability were investigated using SEC, NR-CE, and iCIEF as evaluation indicators.

[0452] The results are shown in Table 19. SEC, NR-CE, and iCIEF data showed that after 4 weeks of storage at 40°C, there were no significant differences among the formulation groups with different concentrations of EDTA-2Na (0.01–1 mg / mL), and all showed good stability.

[0453] Table 19. Screening results for different EDTA-2Na concentrations

[0454] Example 22. Protein Concentration Screening - 1

[0455] Formulations were prepared with different protein concentrations (as shown in Table 20), 20 mM His-HCl, 75 mg / mL sucrose, 0.4 mg / mL PS80, 0.02 mg / mL EDTA-2Na, and pH 5.5. Forced degradation studies (40°C for 4 weeks) were conducted on the samples, and the effects of different protein concentrations on the stability of the formulations were investigated using SEC, NR-CE, and iCIEF as evaluation indicators.

[0456] The results are shown in Table 20. After being placed at 40℃ for 4 weeks, the results showed that there was no significant difference among the formulation groups with protein concentrations of 50–100 mg / mL, and the stability was good.

[0457] Table 20. Protein Concentration Screening Results - 1

[0458] Example 23. Protein Concentration Screening - 2

[0459] Formulations were prepared with different protein concentrations (as shown in Table 21), 20 mM His-HCl, 80 mg / mL sucrose, 0.2 mg / mL PS80, 0.02 mg / mL EDTA-2Na, and pH 5.5. Forced degradation studies (40°C for 4 weeks) were conducted on the samples, and the effects of different protein concentrations on the stability of the formulations were investigated using SEC, NR-CE, and iCIEF as evaluation indicators.

[0460] The results are shown in Table 21. After being placed at 40℃ for 4 weeks, the results showed that there was no significant difference among the formulation groups with protein concentrations ranging from 0.5 to 50 mg / mL, and the stability of all groups was good.

[0461] Table 21. Protein Concentration Screening Results - 2

[0462] Example 24. Long-term stability confirmation

[0463] Formulations were prepared with 1 mg / mL and 50 mg / mL protein, 20 mM His-HCl, 80 mg / mL sucrose, 0.4 mg / mL PS80, 0.02 mg / mL EDTA-2Na, and pH 5.5, respectively. Long-term stability studies were conducted on the samples (stored at 2–8°C for 6 months), using appearance, SEC, NR-CE, and iCIEF as evaluation indicators to assess the long-term stability of the formulations.

[0464] The results are shown in Table 22. Appearance, SEC, NR-CE, and iCIEF data showed that the formulation exhibited good long-term stability after being stored at 2-8℃ for 6 months.

[0465] Table 22 Long-term stability results Note: 2-8℃ M6: Store at 2-8℃ for 6 months.

[0466] Example 25. Formulation of GPC3 / TRGV9 binding protein formulation

[0467] This embodiment provides the following prescription:

[0468] (1) 1 mg / mL GPC3 / TRGV9 binding protein, 20 mM His-HCl, 80 mg / mL sucrose, 0.4 mg / mL PS80, 0.02 mg / mL EDTA-2Na, pH 5.5;

[0469] (2) 0.5 mg / mL GPC3 / TRGV9 binding protein, 20 mM His-HCl, 80 mg / mL sucrose, 0.4 mg / mL PS80, 0.02 mg / mL EDTA-2Na, pH 5.5;

[0470] (3) 2 mg / mL GPC3 / TRGV9 binding protein, 20 mM His-HCl, 80 mg / mL sucrose, 0.4 mg / mL PS80, 0.02 mg / mL EDTA-2Na, pH 5.5;

[0471] (4) 50 mg / mL GPC3 / TRGV9 binding protein, 20 mM His-HCl, 80 mg / mL sucrose, 0.4 mg / mL PS80, 0.02 mg / mL EDTA-2Na, pH 5.5;

[0472] (5) 40 mg / mL GPC3 / TRGV9 binding protein, 20 mM His-HCl, 80 mg / mL sucrose, 0.4 mg / mL PS80, 0.02 mg / mL EDTA-2Na, pH 5.5;

[0473] (6) 60 mg / mL GPC3 / TRGV9 binding protein, 20 mM His-HCl, 80 mg / mL sucrose, 0.4 mg / mL PS80, 0.02 mg / mL EDTA-2Na, pH 5.5;

[0474] (7) 1 mg / mL GPC3 / TRGV9 binding protein, 10 mM His-HCl, 80 mg / mL sucrose, 0.4 mg / mL PS80, 0.02 mg / mL EDTA-2Na, pH 6.0;

[0475] (8) 1 mg / mL GPC3 / TRGV9 binding protein, 30 mM His-HCl, 80 mg / mL sucrose, 0.4 mg / mL PS80, 0.02 mg / mL EDTA-2Na, pH 5.0;

[0476] (9) 50 mg / mL GPC3 / TRGV9 binding protein, 20 mM His-HCl, 60 mg / mL sucrose, 0.4 mg / mL PS80, 0.02 mg / mL EDTA-2Na, pH 5.5;

[0477] (10) 50 mg / mL GPC3 / TRGV9 binding protein, 20 mM His-HCl, 100 mg / mL sucrose, 0.4 mg / mL PS80, 0.02 mg / mL EDTA-2Na, pH 5.5;

[0478] (11) 1 mg / mL GPC3 / TRGV9 binding protein, 20 mM His-HCl, 80 mg / mL sucrose, 0.2 mg / mL PS80, 0.02 mg / mL EDTA-2Na, pH 5.5;

[0479] (12) 1 mg / mL GPC3 / TRGV9 binding protein, 20 mM His-HCl, 80 mg / mL sucrose, 0.6 mg / mL PS80, 0.02 mg / mL EDTA-2Na, pH 5.5;

[0480] (13) 50 mg / mL GPC3 / TRGV9 binding protein, 20 mM His-HCl, 80 mg / mL sucrose, 0.4 mg / mL PS80, 0.01 mg / mL EDTA-2Na, pH 5.5;

[0481] (14) 50 mg / mL GPC3 / TRGV9 binding protein, 20 mM His-HCl, 80 mg / mL sucrose, 0.4 mg / mL PS80, 0.04 mg / mL EDTA-2Na, pH 5.5.

Claims

1. A pharmaceutical composition comprising a GPC3 / TRGV9 binding protein and a buffer; The GPC3 / TRGV9 binding protein includes a first antigen-binding domain that specifically binds to GPC3 and a second antigen-binding domain that specifically binds to TRGV9. The buffer is selected from one or more of acetate buffer, citrate buffer, succinate buffer, histidine buffer, and phosphate buffer; more preferably, it is selected from one or more of acetate-sodium acetate, citrate-sodium citrate, succinate-sodium succinate, histidine-histidine hydrochloride, and disodium hydrogen phosphate-sodium dihydrogen phosphate.

2. The pharmaceutical composition of claim 1, wherein the second antigen-binding domain comprises a single immunoglobulin variable domain, or comprises a heavy chain variable region (VH1) and a light chain variable region (VL1), wherein, The immunoglobulin single variable domain comprises CDR1, CDR2, and CDR3 from any of the amino acid sequences shown in SEQ ID NO: 5 or 26. The VH1 comprises HCDR1, HCDR2, and HCDR3 from any of the amino acid sequences shown in SEQ ID NO: 9 or 27, and the VL1 comprises LCDR1, LCDR2, and LCDR3 from any of the amino acid sequences shown in SEQ ID NO: 10 or 28. The CDR is defined according to the Kabat, IMGT, Chothia, AbM or Contact numbering system; preferably, the CDR is defined according to the Kabat numbering system. Preferably, the immunoglobulin single variable domain comprises CDR1, CDR2, and CDR3 as shown in SEQ ID NO: 6-8, respectively. The VH2 includes HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 11-13, and the VL2 includes LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 14-16.

3. The pharmaceutical composition of claim 2, wherein, The immunoglobulin single variable domain comprises an amino acid sequence as shown in SEQ ID NO: 5 or 26 or having at least 80% or at least 90% identity with it; The VH1 contains an amino acid sequence as shown in or having at least 80% or at least 90% identity with SEQ ID NO: 9 or 27, and the VL1 contains an amino acid sequence as shown in or having at least 80% or at least 90% identity with SEQ ID NO: 10 or 28.

4. The pharmaceutical composition according to any one of claims 1-3, wherein the first antigen-binding domain comprises a heavy chain variable region (VH2) and a light chain variable region (VL2). The VH2 contains HCDR1, HCDR2, and HCDR3 in the amino acid sequence shown in SEQ ID NO:

33. The VL2 contains LCDR1, LCDR2, and LCDR3 from the amino acid sequence shown in SEQ ID NO:

34. The CDR is defined according to the Kabat, IMGT, Chothia, AbM or Contact numbering system; Preferably, VH2 comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 35-37, and VL2 comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 38-40.

5. The pharmaceutical composition of claim 4, wherein, The VH2 contains an amino acid sequence as shown in SEQ ID NO: 33 or having at least 80% or at least 90% identity with it, and the VL2 contains an amino acid sequence as shown in SEQ ID NO: 34 or having at least 80% or at least 90% identity with it.

6. The pharmaceutical composition according to any one of claims 1 to 5, comprising a polypeptide chain selected from any one of (1)-(2): (1) A first heavy chain, a second heavy chain, and a light chain, wherein the first heavy chain comprises an amino acid sequence as shown in or having at least 80% or at least 90% identity with SEQ ID NO: 48, the second heavy chain comprises an amino acid sequence as shown in or having at least 80% or at least 90% identity with SEQ ID NO: 49 or 50, and the light chain comprises an amino acid sequence as shown in or having at least 80% or at least 90% identity with SEQ ID NO: 51; (2) A first heavy chain, a second heavy chain, a first light chain, and a second light chain, wherein the first heavy chain comprises an amino acid sequence as shown in SEQ ID NO: 52 or having at least 80% or at least 90% identity with it, the first light chain comprises an amino acid sequence as shown in SEQ ID NO: 53 or having at least 80% or at least 90% identity with it, the second heavy chain comprises an amino acid sequence as shown in SEQ ID NO: 54 or having at least 80% or at least 90% identity with it, and the second light chain comprises an amino acid sequence as shown in SEQ ID NO: 55 or having at least 80% or at least 90% identity with it.

7. The pharmaceutical composition according to any one of claims 1-6, wherein the pH value of the buffer or the pharmaceutical composition is 3.0-7.0, preferably 4.0-6.

5.

8. The pharmaceutical composition according to any one of claims 1-7, wherein the concentration of the buffer is from 1 mM to 100 mM, preferably from 2 mM to 80 mM, and more preferably from 5 mM to 60 mM.

9. The pharmaceutical composition according to any one of claims 1-8, wherein the concentration of the GPC3 / TRGV9 binding protein is from 0.01 mg / mL to 200 mg / mL, preferably from 0.5 mg / mL to 100 mg / mL, and more preferably from 0.5 mg / mL to 50 mg / mL.

10. The pharmaceutical composition according to any one of claims 1-9, further comprising a surfactant; Preferably, the surfactant is polysorbate or poloxamer, and more preferably polysorbate 20, polysorbate 80 or poloxamer 188; Preferably, the concentration of the surfactant is from 0.01 mg / mL to 5 mg / mL, and more preferably from 0.02 mg / mL to 4.00 mg / mL.

11. The pharmaceutical composition according to any one of claims 1-10, further comprising sugars, preferably sucrose or trehalose; The concentration of the sugar is from 1 mg / mL to 200 mg / mL, preferably from 10 mg / mL to 180 mg / mL, and more preferably from 20 mg / mL to 150 mg / mL.

12. The pharmaceutical composition according to any one of claims 1-11, wherein the pharmaceutical composition further comprises disodium edetate; The concentration of the disodium edetate is from 0.01 mg / mL to 10 mg / mL, preferably from 0.01 mg / mL to 8 mg / mL, and more preferably from 0.01 mg / mL to 2 mg / mL.

13. A pharmaceutical composition comprising: (1) GPC3 / TRGV9 binding protein at concentrations ranging from 0.01 mg / mL to 200 mg / mL, Histidine-histidine hydrochloride from 1 mM to 100 mM Sucrose concentrations ranging from 1 mg / mL to 200 mg / mL Polysorbate 80 from 0.01 mg / mL to 5 mg / mL, and Disodium edetate, ranging from 0.01 mg / mL to 10 mg / mL, The pH of the pharmaceutical composition is 3.0-7.0; or (1-1) GPC3 / TRGV9 binding protein at concentrations ranging from 0.5 mg / mL to 100 mg / mL. 10mM to 50mM histidine-histidine hydrochloride 30 mg / mL to 100 mg / mL sucrose, 0.1 mg / mL to 2 mg / mL polysorbate 80, and 0.01 mg / mL to 1 mg / mL disodium edetate, The pH of the pharmaceutical composition is 5.0-6.0; or (1-2) GPC3 / TRGV9 binding protein at concentrations ranging from 0.5 mg / mL to 100 mg / mL. 10mM to 50mM histidine-histidine hydrochloride 30 mg / mL to 100 mg / mL sucrose, 0.1 mg / mL to 2.00 mg / mL poloxamer 188, and 0.01 mg / mL to 1 mg / mL disodium edetate, The pH of the pharmaceutical composition is 5.0-6.0; or (1-3) 50 mg / mL to 100 mg / mL of GPC3 / TRGV9 binding protein, Approximately 20 mM histidine-histidine hydrochloride, Approximately 75 mg / mL of sucrose. Approximately 0.4 mg / mL of polysorbate 80, and Approximately 0.02 mg / mL of disodium edetate. The pH of the pharmaceutical composition is 5.0-6.0; or (1-4) GPC3 / TRGV9 binding protein at concentrations ranging from 0.5 mg / mL to 50 mg / mL. Approximately 20 mM histidine-histidine hydrochloride, Approximately 80 mg / mL of sucrose, Approximately 0.2 mg / mL of polysorbate 80, and Approximately 0.02 mg / mL of disodium edetate. The pH of the pharmaceutical composition is 5.0-6.0; (2) GPC3 / TRGV9 binding protein at concentrations ranging from 0.01 mg / mL to 200 mg / mL, 1mM to 100mM acetate-sodium acetate, 1 mg / mL to 200 mg / mL sucrose, 0.01 to 5.00 mg / mL polysorbate 80, and 0.01 mg / mL to 10 mg / mL disodium edetate, The pH of the pharmaceutical composition is 3.0-7.0; or (3) GPC3 / TRGV9 binding protein at concentrations ranging from 0.01 mg / mL to 200 mg / mL, 1mM to 100mM citric acid-sodium citrate, 1 mg / mL to 200 mg / mL sucrose, 0.01 to 5.00 mg / mL polysorbate 80, and 0.01 mg / mL to 10 mg / mL disodium edetate, The pH of the pharmaceutical composition is 3.0-7.0; or (4) GPC3 / TRGV9 binding protein at concentrations ranging from 0.01 mg / mL to 200 mg / mL, 1mM to 100mM succinic acid-sodium succinate 1 mg / mL to 200 mg / mL sucrose, 0.01 mg / mL to 5.00 mg / mL polysorbate 80, and 0.01 mg / mL to 10 mg / mL disodium edetate, The pH of the pharmaceutical composition is 3.0-7.0; or (5) GPC3 / TRGV9 binding protein at concentrations ranging from 0.01 mg / mL to 200 mg / mL, 1mM to 100mM disodium hydrogen phosphate-sodium dihydrogen phosphate salt, 1 mg / mL to 200 mg / mL sucrose, 0.01 mg / mL to 5.00 mg / mL polysorbate 80, and 0.01 mg / mL to 10 mg / mL disodium edetate, The pH of the pharmaceutical composition is 3.0-7.0; Preferably, the GPC3 / TRGV9 binding protein is as defined in any one of claims 1-6.

14. A lyophilized formulation obtained by freeze-drying a liquid formulation comprising the pharmaceutical composition of any one of claims 1-13.

15. A reconstituted solution, obtained by reconstituted the lyophilized preparation of claim 14 with a solvent; preferably, the solvent is water, physiological saline or glucose.

16. The pharmaceutical composition according to any one of claims 1-13, or the reconstituted solution according to claim 15; wherein it is an intravenous injection, subcutaneous injection, intraperitoneal injection or intramuscular injection; preferably an intravenous or subcutaneous injection.

17. An article comprising a container containing a pharmaceutical composition as claimed in any one of claims 1-13, a lyophilized formulation as claimed in claim 14, or a reconstituted solution as claimed in claim 15.

18. A method of treating or preventing a disease, comprising administering to a subject in need a therapeutically or preventively effective amount of the pharmaceutical composition of any one of claims 1-13, the lyophilized formulation of claim 14, the reconstituted solution of claim 15, or the article of claim 17, wherein: The preferred disease is cancer. More preferably, the cancer is a liver cancer or a GPC3-positive cancer, most preferably a GPC3-positive liver cancer.